2020-07-07T09:19:57-05:00 2019-09-30 GRANT THORNTON LLP 757 THIRD AVENUE 3RD FLOOR NEW YORK NY 100172013 990 2018-10-01 133163817 THE FOUNDATION FOR AIDS RESEARCH % BRADLEY JENSEN FOUN 2128061600 120 WALL STREET 13TH FLOOR NEW YORK NY 100053908 BRADLEY JENSEN ASSISTANT TREAS./CFO 2128061703 2020-07-06 true Scott Thompsett P00741490 2125990100 69.248.129.53 26377520201895000003 2020-07-07 P 53F3E6840D653250BC02858DC60F5F1014CD29E2 8DDBE17DE0599195D17B7973BC5944EE8AD8D13D 2018 2020-11-06 18:47:13Z AIDS RESEARCH FOUNDATION OR AMFAR KEVIN FROST 120 WALL STREET 13TH FLOOR NEW YORK NY 10005 67171723 false X WWW.AMFAR.ORG X 1983 NY AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. 12 12 94 0 0 0 42784390 40275703 0 0 1668073 2262943 -12144387 -11197256 32308076 31341390 12574033 10109752 0 0 11259330 11146319 735053 747847 5823450 14468481 12968286 39036897 34972204 -6728821 -3630814 69536136 64157103 16985457 14672542 52550679 49484561 X THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMFS LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARCH false false 15340994 8045603 0 RESEARCH: AMFAR SUPPORTS RESEARCH PROJECTS THAT EXPLORE NOVEL APPROACHES TO SCIENTIFICALLY SOUND BUT UNTESTED HYPOTHESES IN ALL AREAS OF RESEARCH ON HIV/AIDS, FUNDING GOAL-ORIENTED STUDIES THAT OFTEN LACK THE PRELIMINARY DATA REQUIRED FOR SUPPORT FROM TRADITIONAL GRANT MAKERS. THE FOUNDATION PLAYS A VITAL ROLE IN HIV/AIDS RESEARCH, IDENTIFYING CRITICAL GAPS IN KNOWLEDGE AND PROVIDING ESSENTIAL SEED MONEY THAT ENABLES GRANTEES AND FELLOWS TO TEST THE MERITS OF NEW CONCEPTS OR TECHNOLOGIES THAT SUBSEQUENTLY CAN BE VALIDATED THROUGH LARGE-SCALE STUDIES, SUCH AS THOSE FUNDED BY THE U.S. NATIONAL INSTITUTES OF HEALTH. FOR FURTHER DETAILS, SEE SCHEDULE O. 4670239 1891311 0 TREAT ASIA: AMFARS TREAT ASIA (THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING IN ASIA) PROGRAM IS A NETWORK OF HOSPITALS, CLINICS, AND RESEARCH INSTITUTIONS WORKING WITH CIVIL SOCIETY TO ENSURE THE SAFE AND EFFECTIVE DELIVERY OF TREATMENTS FOR HIV AND ITS CO-INFECTIONS TO ADULTS AND CHILDREN ACROSS THE ASIA-PACIFIC THROUGH RESEARCH, EDUCATION, AND ADVOCACY OF EVIDENCE-BASED HIV-RELATED POLICIES. THE TREAT ASIA NETWORK ENCOMPASSES 21 ADULT AND 20 PEDIATRIC SITES THROUGHOUT THE REGION, WHICH COLLABORATE ON A VARIETY OF PROJECTS. FOR FURTHER DETAILS, SEE SCHEDULE O. 4097084 0 0 PUBLIC INFORMATION: AMFAR SEEKS TO TRANSLATE AND DISSEMINATE INFORMATION ON IMPORTANT HIV-RELATED RESEARCH, TREATMENT, PREVENTION, AND POLICY ISSUES FOR DIVERSE AUDIENCES AND TO INCREASE AWARENESS AND KNOWLEDGE OF THE PANDEMIC. AMFAR PUBLISHES A WIDE RANGE OF EDUCATIONAL MATERIALS, MAINTAINS AN INFORMATIVE WEBSITE, AND ENGAGES RESPECTED PUBLIC FIGURES, HIV/AIDS SCIENTISTS, AND POLICYMAKERS IN COMMUNICATING THE NEED FOR CONTINUED RESEARCH TO DEVELOP NEW METHODS OF PREVENTION, TREATMENT, AND, ULTIMATELY, A CURE FOR HIV. FOR FURTHER DETAILS, SEE SCHEDULE O. 2049139 77995 0 public policy 268341 94843 0 GMT Initiative 2317480 172838 0 26425797 true true false true false false false true false true true false false false true true true false false true true true false true true false false true false true false false false false false false false false true false false false false false false false false true 124 0 true 94 true false true TH false false false true true false false false false false false X 12 12 false false false false false false false true true false false true true true true true true true true false AL AR CA FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NY NC OK OR PA RI SC TN UT VA WV WI X X BRADLEY JENSEN 2128061703 120 WALL STREET 13TH FLOOR NEW YORK NY 100053908 Bill Roedy Chairman of the Board 1.0 0.0 X X 0 0 0 Cindy Rachofsky Vice Chairman 1.0 0.0 X X 0 0 0 Arlen H Andelson Secretary 1.0 0.0 X X 0 0 0 Raymond F Schinazi PhD Treasurer (As of 03/19) 1.0 0.0 X X 0 0 0 Michael J Klingensmith Treasurer (Thru 03/19) 1.0 0.0 X X 0 0 0 David Bohnett Trustee 1.0 0.0 X 0 0 0 Zev Braun Trustee (NON-VOTING) 1.0 0.0 X 0 0 0 Jonathan S Canno Trustee (Thru 02/19) 1.0 0.0 X 0 0 0 Jay Ellis Trustee 1.0 0.0 X 0 0 0 Aileen Getty Trustee 1.0 0.0 X 0 0 0 T Ryan Greenwalt Trustee (as of 2/19) 1.0 0.0 X 0 0 0 Michele V McNeill PharmD Trustee (NON-VOTING) 1.0 0.0 X 0 0 0 Edward Milstein Trustee 1.0 0.0 X 0 0 0 Alan D Schwartz Trustee 1.0 0.0 X 0 0 0 Mario Stevenson Trustee 1.0 0.0 X 0 0 0 Phill Wilson Trustee (as of 2/19) 1.0 0.0 X 0 0 0 Kevin Frost Chief Executive Officer 40.0 0.0 X 480408 0 93432 Bradley Jensen Assistant Treasurer, CFO 40.0 0.0 X 268290 0 62167 Rowena Johnston ASST SEC, VP, RESEARCH 40.0 0.0 X 207188 0 32709 Edward Donnelly Asst Treasurer, Controller 40.0 0.0 X 165914 0 33007 Eric Muscatell Vice President of Development 40.0 0.0 X 219278 0 34529 Annette Sohn Vice President, TREAT Asia PGM 40.0 0.0 X 235284 0 25131 AnnMarie Shannahan Vice President, Public Info. 40.0 0.0 X 237680 0 45538 Gregorio Millet Vice President, Public Policy 40.0 0.0 X 186211 0 56072 Andrew McInness Director, Publications 40.0 0.0 X 170102 0 67984 Anthony Ancona Vice President, Human Resource 40.0 0.0 X 192931 0 31716 Susan Doster Chief Technology Officer 40.0 0.0 X 149888 0 52030 JONATHAN KEY DIRECTOR, PHILANTHROPY 40.0 0.0 X 193887 0 57103 Sebastian Gheith Associate Counsel 40.0 0.0 X 169030 0 67978 2876091 0 659396 28 false true false AAB PRODUCTION INC 64 ALLEN ROAD 5TH FLOOR NEW YORK NY 10002 Events Production 623887 PATTERSON BELKNAP WEBB TYLER LLP 1133 Avenue of the Americas NEW YORK NY 100366710 LEGAL SERVICES 512837 JOSH WOODS PRODUCTION 39 WEST 14TH STREET SUITE 504 NEW YORK NY 10011 Events Production 315500 EIDOLON COMMUNICATIONS INC 15 MAIDEN LANE SUITE 1401 NEW YORK NY 10038 DIRECT MAIL/CONSULT. 286181 INCA INTERNATIONAL PRODUCTIONS INC 40 WORTH STREET SUITE 827 NEW YORK NY 10013 Events Production 284783 13 90281 27896470 6017798 6271154 63158 40275703 0 1492677 1492677 0 45654 45654 0 0 0 23533474 1455 22764663 768811 1455 770266 770266 1794170 27896470 13056389 -11262219 -11262219 0 0 0 25294 9281 16013 16013 STORE SALES 900099 1859 1859 LIST RENTALS 900099 170 170 MISCELLANEOUS INCOME 900099 1267 1267 3296 31341390 -8934313 X 6879084 6879084 0 3230668 3230668 0 2522218 1837955 326246 358017 0 6087863 4025651 676870 1385342 378518 247419 43798 87301 1637261 1057777 229336 350148 520459 336756 65216 118487 0 -4808 -9150 4324 18 196725 196725 123466 123466 747847 747847 277449 277449 1366933 907234 34283 425416 346932 309763 1993 35176 68296 41715 7387 19194 205549 155635 21016 28898 0 1517346 1086453 171818 259075 1236674 476254 2221 758199 0 510065 493801 4190 12074 0 0 446165 324244 51322 70599 364337 264776 41910 57651 PROGRAM MATERIALS 2230607 2230607 PROGRAM TECHNICAL SUPPORT 836863 836863 BAD DEBT EXPENSE 631150 458679 72601 99870 PRINTING 550024 121353 1072 427599 2064513 988794 493180 582539 34972204 26425797 2722957 5823450 X 518072 156353 0 361719 5477346 6826913 691606 1423450 699100 867952 6388976 6339168 0 0 0 0 0 0 425761 413307 1960938 2003877 7298048 4497236 2921534 2800812 48872134 42758997 0 0 0 0 0 0 2098741 722627 69536136 64157103 3655122 2769299 2768840 2086068 8596427 7947789 0 0 0 0 0 0 0 0 0 0 1965068 1869386 16985457 14672542 X 48668968 45254909 3509128 3850319 372583 379333 52550679 49484561 69536136 64157103 -3630814 564696 X false true X true true true X 56251128 58810206 50842378 42784390 40275703 248963805 0 0 56251128 58810206 50842378 42784390 40275703 248963805 0 248963805 1652775 1316372 1354513 1590672 1538331 7452663 0 2103589 2246081 1819001 2097498 1822760 10088929 266505397 0.93418 0.93335 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false false false true 391838 391838 false false LOBBYING EXPENSES PART II-B THE FOUNDATION FOR AIDS RESEARCH DEVELOPED AN ACTION AGENDA TO END AIDS THAT IDENTIFIED CRITICAL DECISIONS THAT NEED TO BE MADE TO ADVANCE EVIDENCE BASED AIDS POLICIES. WE CREATED A VARIETY OF ISSUE BRIEFS ON TOPICS SUCH AS THE POTENTIAL IMPACT OF VARIOUS BUDGET SCENARIOS ON GLOBAL HEALTH SERVICES, AND POLICY PRIORITIES TO ADDRESS THE HIV EPIDEMIC AMONG GAY MEN IN THE US. THESE ISSUE BRIEFS WERE SHARED WITH CAPITOL HILL STAFF AND MEMBERS OF THE ADMINISTRATION. AMFAR MET REGULARLY WITH STAFF TO MEMBERS OF CONGRESS AND WITH ADMINISTRATION STAFF, AND WE PROVIDED INPUT TO THE ADMINISTRATION ON DEVELOPMENT OF THE PEPFAR BLUEPRINT FOR AN AIDS FREE GENERATION. AMFAR SPONSORED SEVERAL BRIEFINGS ON CAPITOL HILL ON AIDS POLICY AND RESEARCH ISSUES. AMFAR USES THESE BRIEFINGS AS AN EDUCATIONAL TOOL. The Foundation engaged an independent consultant to engage in lobbying activities on its behalf. Fees paid to this consultant totaled $123,466 in the fiscal year ending September 30, 2019. 459230 X Donated Items, Inventory etc. true 684111 6750 10507 701368 593133 4100 86877 684110 541231 5950 45952 593133 493036 7293 40902 541231 490979 7998 -5941 493036 0.54080 0.45920 false false 2542490 585427 1957063 304826 303430 1396 4450732 3608379 842353 2800812 0 LONG TERM LEASE LIABILITY 1572406 SEC. 457 RETIREMENT LIABILITY 296980 1869386 X 31715076 564696 87894 -1455 651135 31063941 277449 277449 31341390 34781194 87894 -1455 86439 34694755 277449 277449 34972204 ENDOWMENTS PART V, LINE 4 AMFAR'S ENDOWMENT FUND IS INTENDED TO FUND THE VARIOUS GENERAL RESEARCH PROGRAMS THE ORGANIZATION SPONSORS. Reconciliation of Revenue & Expenses Part XI & Part XII, Line 2d Loss/Gain on Disposal of Fixed Assets $-1,455 FIN 48 - INCOME TAXES AMFAR FOLLOWS GUIDANCE THAT CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, INCLUDING ISSUES RELATING TO FINANCIAL STATEMENT RECOGNITION AND GUIDANCE ON MEASUREMENT. THIS GUIDANCE PROVIDES THAT THE TAX EFFECTS FROM AN UNCERTAIN TAX POSITION CAN ONLY BE RECOGNIZED IN THE FINANCIAL STATEMENTS IF THE POSITION IS "MORE-LIKELY-THAN-NOT" TO BE SUSTAINED IF THE POSITION WERE TO BE CHALLENGED BY A TAXING AUTHORITY. THE ASSESSMENT OF THE TAX POSITION IS BASED SOLELY ON THE TECHNICAL MERITS OF THE POSITION, WITHOUT REGARD TO THE LIKELIHOOD THAT THE TAX POSITION MAY BE CHALLENGED. AMFAR IS EXEMPT FROM FEDERAL INCOME TAX UNDER IRC SECTION 501(C)(3), THOUGH IT IS SUBJECT TO TAX ON INCOME UNRELATED TO ITS EXEMPT PURPOSE, UNLESS THAT INCOME IS OTHERWISE EXCLUDED BY THE CODE. AMFAR HAS PROCESSES PRESENTLY IN PLACE TO ENSURE THE MAINTENANCE OF ITS TAX-EXEMPT STATUS; TO IDENTIFY AND REPORT UNRELATED INCOME; TO DETERMINE ITS FILING AND TAX OBLIGATIONS IN JURISDICTIONS FOR WHICH IT WAS NEXUS; AND TO IDENTIFY AND EVALUATE OTHER MATTERS THAT MAY BE CONSIDERED TAX POSITIONS. AMFAR HAS DETERMINED THAT THERE ARE NO MATERIAL UNCERTAIN TAX POSITIONS THAT REQUIRE RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS. COLLECTIONS OF ART, HISTORICAL TREASURES, OR OTHER SIMILAR ASSETS PART III, LINE 4 AMFAR HOLDS VARIOUS ITEMS OF JEWELRY, PHOTOGRAPHS AND OTHER ITEMS OF ARTISTIC VALUE THAT HAVE BEEN DONATED TO THE ORGANIZATION FOR SALE AT SPECIAL EVENTS. THE ORGANIZATION HAS MAINTAINED THESE ITEMS IN INVENTORY FOR A FEW YEARS AND IS IN THE PROCESS OF SELLING THEM. true East Asia and the Pacific Grantmaking n/a 1885978 Europe (Including Iceland and Greenland) Grantmaking N/A 1031960 North America Grantmaking N/A 75000 South Asia Grantmaking N/A 63568 Sub-Saharan Africa Grantmaking N/A 174161 East Asia and the Pacific 1 15 Program Services Therapeutics, Training 1855984 East Asia and the Pacific Fundraising N/A 1563509 Europe (Including Iceland and Greenland) Fundraising N/A 8408176 South America Fundraising N/A 290459 1 15 1 15 15348795 15348795 East Asia/Pacific BASIC RESEARCH 249961 wire transfe 0 East Asia/Pacific BASIC RESEARCH 24828 wire transfe 0 East Asia/Pacific BASIC RESEARCH 37500 wire transfe 0 East Asia/Pacific GMT INITIATIVE 46153 wire transfe 0 East Asia/Pacific TREAT ASIA 31251 wire transfe 0 East Asia/Pacific TREAT ASIA 20848 wire transfe 0 East Asia/Pacific TREAT ASIA 6245 wire transfe 0 East Asia/Pacific TREAT ASIA 19995 wire transfe 0 East Asia/Pacific TREAT ASIA 14925 wire transfe 0 East Asia/Pacific TREAT ASIA 15450 wire transfe 0 East Asia/Pacific TREAT ASIA 9861 wire transfe 0 East Asia/Pacific TREAT ASIA 21208 wire transfe 0 East Asia/Pacific TREAT ASIA 16700 wire transfe 0 East Asia/Pacific TREAT ASIA 20490 wire transfe 0 East Asia/Pacific TREAT ASIA 22686 wire transfe 0 East Asia/Pacific TREAT ASIA 21688 wire transfe 0 East Asia/Pacific TREAT ASIA 21582 wire transfe 0 East Asia/Pacific TREAT ASIA 23528 wire transfe 0 East Asia/Pacific TREAT ASIA 20993 wire transfe 0 East Asia/Pacific TREAT ASIA 21236 wire transfe 0 East Asia/Pacific TREAT ASIA 15570 wire transfe 0 East Asia/Pacific TREAT ASIA 23212 wire transfe 0 East Asia/Pacific TREAT ASIA 21368 wire transfe 0 East Asia/Pacific TREAT ASIA 21228 wire transfe 0 East Asia/Pacific TREAT ASIA 79383 wire transfe 0 East Asia/Pacific TREAT ASIA 7500 wire transfe 0 East Asia/Pacific TREAT ASIA 7350 wire transfe 0 East Asia/Pacific TREAT ASIA 6450 wire transfe 0 East Asia/Pacific TREAT ASIA 6150 wire transfe 0 East Asia/Pacific TREAT ASIA 6600 wire transfe 0 East Asia/Pacific TREAT ASIA 7500 wire transfe 0 East Asia/Pacific TREAT ASIA 7425 wire transfe 0 East Asia/Pacific TREAT ASIA 7500 wire transfe 0 East Asia/Pacific TREAT ASIA 7500 wire transfe 0 East Asia/Pacific TREAT ASIA 7500 wire transfe 0 East Asia/Pacific TREAT ASIA 235373 wire transfe 0 East Asia/Pacific TREAT ASIA 199262 wire transfe 0 East Asia/Pacific TREAT ASIA 79357 wire transfe 0 East Asia/Pacific TREAT ASIA 7500 wire transfe 0 East Asia/Pacific TREAT ASIA 7500 wire transfe 0 East Asia/Pacific TREAT ASIA 15000 wire transfe 0 East Asia/Pacific TREAT ASIA 14988 wire transfe 0 East Asia/Pacific TREAT ASIA 7500 wire transfe 0 East Asia/Pacific TREAT ASIA 24500 wire transfe 0 East Asia/Pacific TREAT ASIA 20000 wire transfe 0 East Asia/Pacific TREAT ASIA 10705 wire transfe 0 East Asia/Pacific TREAT ASIA 8110 wire transfe 0 East Asia/Pacific TREAT ASIA 7154 wire transfe 0 East Asia/Pacific TREAT ASIA 6156 wire transfe 0 East Asia/Pacific TREAT ASIA 7928 wire transfe 0 East Asia/Pacific TREAT ASIA 20357 wire transfe 0 East Asia/Pacific TREAT ASIA 7820 wire transfe 0 East Asia/Pacific TREAT ASIA 62732 wire transfe 0 East Asia/Pacific TREAT ASIA 9242 wire transfe 0 East Asia/Pacific TREAT ASIA 124794 wire transfe 0 East Asia/Pacific TREAT ASIA 8999 wire transfe 0 East Asia/Pacific TREAT ASIA 10400 wire transfe 0 East Asia/Pacific TREAT ASIA 7900 wire transfe 0 East Asia/Pacific TREAT ASIA 8000 wire transfe 0 East Asia/Pacific TREAT ASIA 5832 wire transfe 0 East Asia/Pacific TREAT ASIA 8000 wire transfe 0 East Asia/Pacific TREAT ASIA 8000 wire transfe 0 East Asia/Pacific TREAT ASIA 6500 wire transfe 0 East Asia/Pacific TREAT ASIA 5625 wire transfe 0 Europe BASIC RESEARCH 73333 wire transfe 0 Europe BASIC RESEARCH 45000 wire transfe 0 Europe RESEARCH 141077 wire transfe 0 Europe RESEARCH 365143 wire transfe 0 Europe RESEARCH 60000 wire transfe 0 Europe RESEARCH 429468 wire transfe 0 North America (excl USA) BASIC RESEARCH 75000 wire transfe 0 South Asia TREAT ASIA 19078 wire transfe 0 South Asia TREAT ASIA 19974 wire transfe 0 South Asia TREAT ASIA 7500 wire transfe 0 South Asia TREAT ASIA 17016 wire transfe 0 Sub-Saharan Africa BASIC RESEARCH 24998 wire transfe 0 Sub-Saharan Africa BASIC RESEARCH 24698 wire transfe 0 Sub-Saharan Africa BASIC RESEARCH 24998 wire transfe 0 Sub-Saharan Africa PUBLIC POLICY 30000 wire transfe 0 Sub-Saharan Africa TREAT ASIA 64351 wire transfe 0 Sub-Saharan Africa TREAT ASIA 5041 wire transfe 0 Sub-Saharan Africa TREAT ASIA 7647 wire transfe 0 82 false false false false false false FOREIGN ACTIVITIES PART I, LINE 2 INTERNATIONAL ORGANIZATIONS ARE RECOMMENDED FOR FUNDING BASED UPON THE RESULTS OF COMMUNITY-BASED PEER REVIEW AND/OR PROGRAM STAFF ASSESSMENT OF PROPOSAL MERIT AND ORGANIZATION CAPACITY TO UNDERTAKE PROPOSED PROJECTS THAT ARE CHARITABLE IN PURPOSE. PRE-AWARD DUE-DILIGENCE FOR NEW INTERNATIONAL GRANTEES INCLUDES REVIEW OF ORGANIZATION DOCUMENTS AND REGISTRATIONS TO VERIFY THAT THE ORGANIZATION OPERATES FOR A CHARITABLE PURPOSE AND THAT BASIC CAPACITY FOR PROJECT OVERSIGHT AND GOVERNANCE HAS BEEN ESTABLISHED. ALL INTERNATIONAL GRANTEES ARE REQUIRED TO REPORT SEMI-ANNUALLY ON PROJECT PROGRESS AND EXPENDITURES; CONTINUED REPORTING IS REQUIRED UNTIL SUCH TIME AS GRANT FUNDS ARE EXPENDED IN FULL. REPORTS ARE REVIEWED BY ADMINISTRATIVE AND PROGRAM STAFF. ADDITIONAL OVERSIGHT IS PROVIDED AS NECESSARY BY MEANS OF ONGOING, INFORMAL CONTACT WITH SITES REGARDING PROGRESS AND TECHNICAL ISSUES AND SITE VISITS WHERE FEASIBLE. INTERNATIONAL RESEARCH GRANT RECIPIENTS SUBMIT AN INTERIM AND A FINAL PROGRESS REPORTING ADDITION TO EXPENDITURES REPORTS DUE FOLLOWING THE ENDS OF THE 2ND, 3RD AND FINAL QUARTERS OF THE PERFORMANCE PERIOD. FOREIGN ACTIVITIES PART I, LINE 3, COLUMN D THE FOUNDATION FOR AIDS RESEARCH CONDUCTS MANY OF ITS GRANT-MAKING PROGRAM SERVICES (SEE PART III OF FORM 990) IN U.S. AND FOREIGN JURISDICTIONS. IN COLUMN D, THE ORGANIZATION HAS REPORTED THE BASIC PROGRAM THESE GRANTS SUPPORT; PLEASE REFER TO PART III FOR MORE INFORMATION ABOUT THESE PROGRAMS/INITIATIVES. FOREIGN ACTIVITIES - STATUS OF GRANTEES THE FOUNDATION FOR AIDS RESEARCH SUPPORTS MANY NON-U.S. ORGANIZATIONS IN THE FIGHT AGAINST AIDS AND HIV-RELATED DISEASES. FOR PURPOSES OF SCHEDULE F, PART II, LINE 2 - ALL 82 CHARITIES SUPPORTED ARE PRESUMED TO BE THE EQUIVALENT OF U.S. CHARITIES. X X X X X X true aab productions INC events production false 20306722 550543 19756179 Josh Woods Production events production false 3941393 361400 3579993 EIDOLON COMM INC direct mail false 850329 192503 657827 Sanky Comm Inc direct mail false 158254 135463 22791 25256698 1239909 24016790 AL AK AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN TX UT VA WA WV WI Cannes 13695811 13244311 451500 1071064 382908 1832283 3657242 Dallas 5526933 5324413 202520 257624 226613 248752 801539 18 10467896 9327746 1140150 442774 730059 1559893 1845638 29690640 27896470 1794170 1771462 1339580 3640928 6304419 13056389 -11262219 SCHEDULE G, PART I THE FOUNDATION FOR AIDS RESEARCH ACTUALLY PAID OUT $747,847 IN FUNDRAISING EXPENSES FOR THE YEAR ENDING SEPTEMBER 30, 2019. THIS AMOUNT IS REPORTED ON PART IX, LINE 11(E). FOR PURPOSES OF SCHEDULE G, THE FOUNDATION IS REPORTING ALL AMOUNTS PAID TO THE CONSULTANTS LISTED ON PART I, REGARDLESS OF WHETHER SUCH AMOUNTS WERE PURE FUNDRAISING EXPENSES OR EVENT PRODUCTION COSTS. ON SCHEDULE G, THE TOTAL AMOUNT PAID TO THE ORGANIZATIONS LISTED IS $1,239,909. OF THAT $1,239,909, ONLY $747,847 WAS PAID FOR FUNDRAISING SERVICES, THE REMAINING $492,062 WAS PAID FOR EVENT PRODUCTION SERVICES. IN THE INTERESTS OF CLARITY, THE FOUNDATION WOULD ALSO LIKE TO MAKE CLEAR THAT THE COMPENSATION REPORTED AS HAVING BEEN PAID TO THE PROFESSIONAL FUNDRAISERS REPORTED ON SCHEDULE G IS REPORTED ON A FISCAL YEAR BASIS. SOME OF THOSE SAME FUNDRAISERS ARE REPORTED ON THE FOUNDATION'S TOP 5 HIGHEST PAID INDEPENDENT CONTRACTORS LIST (IN SCHEDULE O). IN COMPLIANCE WITH THE INSTRUCTIONS TO THE FORM 990, COMPENSATION REPORTED FOR PART VII (AND LISTED IN SCHEDULE O) IS REPORTED ON A CALENDAR YEAR BASIS. ACCORDINGLY, AMOUNTS ON PART VII AND SCHEDULE G WILL NOT RECONCILE. true The Rockefeller University 1230 York Avenue New York NY 10065 131624158 501(c)(3) 13394 0 BASIC RESEARCH Beth Israel Deaconess Medical Center 330 Brookline Avenue Boston MA 02215 042103881 501(c)(3) 213426 0 BASIC RESEARCH Regents of the University of CA San Francisco 3333 California St San Francisco CA 94143 946036493 501(c)(3) 374968 0 BASIC RESEARCH Foundation for the National Inst of Health 9650 Rockville Pike Bethesda MD 208143999 521986675 501(c)(3) 13334 0 BASIC RESEARCH Mayo Clinic College of Medicine 200 First Street SW Rochester MN 55905 416011702 501(c)(3) 42858 0 BASIC RESEARCH Oregon Health and Science University 3181 SW Sam Jackson Park Portland OR 97239 931176109 501(c)(3) 42848 0 BASIC RESEARCH Boston University School of Medicine 650 Albany St EBRC 640 Boston MA 02118 043314093 501(c)(3) 75001 0 BASIC RESEARCH Fred Hutchinson Cancer Research Center 1100 Fairview Ave N Seattle WA 98109 237156071 501(c)(3) 68615 0 BASIC RESEARCH University of Maryland at Baltimore 725 Lombard St S615 Baltimore MD 21201 526002033 501(c)(3) 60001 0 BASIC RESEARCH Fred Hutchinson Cancer Research Center 1100 Fairview Ave N Seattle WA 98109 237156071 501(c)(3) 42858 0 BASIC RESEARCH International AIDS Vaccine Initiative 125 Broad St 9th Fl New York NY 10004 133870223 501(c)(3) 74759 0 BASIC RESEARCH Weill Medical College of Cornell University 1300 York Avenue New York NY 10065 131623978 501(c)(3) 145534 0 BASIC RESEARCH The Scripps Research Institute 130 Scripps Way La Jolla CA 33458 330435954 501(c)(3) 75000 0 BASIC RESEARCH Emory University 1599 Clifton Rd Atlanta GA 303224250 580566256 501(c)(3) 75000 0 BASIC RESEARCH State University of New York at Buffalo 520 Le Entrance Ste 211 Amherst NY 14228 916001537 501(c)(3) 16666 0 BASIC RESEARCH Northwestern University Searle 6-512 320 E Chicago IL 60611 362167817 501(c)(3) 76416 0 BASIC RESEARCH The Wistar Institute 3601 Spruce Street Philadelphia PA 19104 236434390 501(c)(3) 65002 0 BASIC RESEARCH The Brigham and Women's Hospital Inc 75 Francis Street Boston MA 02115 042312909 501(c)(3) 50002 0 BASIC RESEARCH Harvard Pilgrim Health Care Institute 93 WORCESTER St STE 100 Wellesley MA 02481 042452600 501(c)(3) 66540 0 BASIC RESEARCH National Institutes of Health 40 Convent Drive Bethesda MD 20892 115 75000 0 BASIC RESEARCH Johns Hopkins University 733 N BRDWY MRB 117 Baltimore MD 21205 520595110 501(c)(3) 102261 0 GMT INITIATIVE Black AIDS Institute 1833 West Eigth 200 Los Angeles CA 90057 954742741 501(c)(3) 25000 0 PREVENTION SCIENCE OUTREACH Schwab Charitable Fund PO Box 628298 Orlando FL 328628298 311640316 501(c)(3) 45000 0 PREVENTION SCIENCE OUTREACH Health GAP (Global Access Project) 81 Prospect StREET Brooklyn NY 11201 205053765 501(c)(3) 47995 0 PUBLIC POLICY University of California San Francisco 3333 California St San Francisco CA 94143 946036493 501(c)(3) 3219544 0 RESEARCH Harvard University 29 Oxford Street Cambridge MA 02138 042103580 501(c)(3) 130106 0 RESEARCH Regents of the University of Minnesota 200 Oak Street Minneapolis MN 554552070 416007513 501(c)(3) 110096 0 RESEARCH University of Washington 4333 Brooklyn Ave Seattle WA 981959472 916001537 501(c)(3) 283681 0 RESEARCH Johns Hopkins University 733 N BRDWY MRB 117 Baltimore MD 21205 520595110 501(c)(3) 333487 0 RESEARCH Trustees of the University of Pa 3451 Walnut St Philadelphia PA 191046250 231352685 501(c)(3) 311171 0 RESEARCH Johns Hopkins University 733 N BRDWY MRB 117 Baltimore MD 21205 520595110 501(c)(3) 192460 0 RESEARCH The Brigham and Women's Hospital Inc 75 Francis Street Boston MA 02115 042312909 501(c)(3) 50597 0 RESEARCH Johns Hopkins University 733 N BRDWY MRB 117 Baltimore MD 21205 520595110 501(c)(3) 178167 0 TREAT ASIA Massachusetts General Hospital 101 Huntington Ave 300 Boston MA 02199 042697983 501(c)(3) 30000 0 TREAT ASIA 34 GRANTS AND ASSISTANCE PART I, LINE 2 AMFAR PROVIDES GRANTS AND FELLOWSHIPS TO INDEPENDENT NOT-FOR-PROFIT ORGANIZATIONS THROUGH A PEER-REVIEW PROCESS. GRANT APPLICATIONS ARE FIRST REVIEWED BY THE FOUNDATION'S VOLUNTEER SCIENTIFIC ADVISORY COMMITTEE, WHICH COMPRISES RECOGNIZED EXPERTS IN THE MEDICAL, SCIENTIFIC, AND SOCIAL SCIENCES DISCIPLINES RELEVANT TO HIV AND AIDS. THE SCIENTIFIC ADVISORY COMMITTEE THEN SENDS ITS EVALUATIONS TO ONE OF THE THREE COMMITTEES (RESEARCH, GLOBAL INITIATIVES OR PUBLIC POLICY) OF THE FOUNDATION'S PROGRAM BOARD, WHICH SERVES IN AN ADVISORY CAPACITY TO THE BOARD OF TRUSTEES. AFTER A PROGRAM COMMITTEE HAS COMPLETED ITS REVIEW OF THE APPLICATIONS, IT PRESENTS ITS FUNDING RECOMMENDATIONS TO AMFAR'S EXECUTIVE COMMITTEE AND/OR THE FULL BOARD OF TRUSTEES FOR FINAL APPROVAL AND FUNDING AUTHORIZATION. GRANTS AND FELLOWSHIPS ARE PAYABLE OVER A ONE-TO-THREE-YEAR PERIOD, AND ARE REVOCABLE AT AMFAR'S OPTION IF THE RECIPIENT'S PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE TERMS OF THE GRANT OR FELLOWSHIPS. IN CERTAIN CASES, THE ACTUAL AMOUNTS PAID UNDER GRANTS AND FELLOWSHIP AWARDS MAY BE LESS THAN THE ORIGINAL AWARD IF THE RECIPIENT DOES NOT USE THE FULL AMOUNT AWARDED. THEREFORE, A RESERVE FOR UNEXPENDED GRANTS AND FELLOWSHIPS HAS BEEN RECORDED. SUBAWARDS ARE GRANTS AWARDED TO NOT-FOR-PROFIT ORGANIZATIONS TO SUPPORT THE COSTS OF COLLABORATION AND PARTICIPATION IN HIV/AIDS-RELATED RESEARCH PROJECTS FOR WHICH AMFAR HAS SECURED RESTRICTED FUNDS. SUBAWARDS ARE PAYABLE OVER A ONE-YEAR PERIOD, ALTHOUGH ADVANCE PAYMENTS, IN FULL OR IN PART, MAY BE ISSUED FOLLOWING EXECUTION OF THE SUBAWARD AGREEMENT. SUBAWARDS ARE CONTINGENT UPON THE AVAILABILITY OF FUNDS AND ARE REVOCABLE IF THE RECIPIENTS' PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE SUBAWARD TERMS. X X X X false true false false false false false false false Kevin Frost Chief Executive Officer 424771 0 0 0 55637 0 37750 0 59271 0 577429 0 0 0 Bradley Jensen Assistant Treasurer, CFO 268290 0 0 0 0 0 19104 0 43063 0 330457 0 0 0 Rowena Johnston ASST SEC, VP, RESEARCH 207188 0 0 0 0 0 14564 0 18145 0 239897 0 0 0 Edward Donnelly Asst Treasurer, Controller 165914 0 0 0 0 0 16384 0 16623 0 198921 0 0 0 Eric Muscatell Vice President of Development 219278 0 0 0 0 0 16384 0 18145 0 253807 0 0 0 Annette Sohn Vice President, TREAT Asia PGM 235284 0 0 0 0 0 17391 0 7740 0 260415 0 0 0 AnnMarie Shannahan Vice President, Public Info. 237680 0 0 0 0 0 16803 0 28735 0 283218 0 0 0 Gregorio Millet Vice President, Public Policy 186211 0 0 0 0 0 14109 0 41963 0 242283 0 0 0 Andrew McInness Director, Publications 170102 0 0 0 0 0 12256 0 55728 0 238086 0 0 0 Anthony Ancona Vice President, Human Resource 192931 0 0 0 0 0 13571 0 18145 0 224647 0 0 0 Susan Doster Chief Technology Officer 149888 0 0 0 0 0 11132 0 40898 0 201918 0 0 0 JONATHAN KEY DIRECTOR, PHILANTHROPY 193887 0 0 0 0 0 14040 0 43063 0 250990 0 0 0 Sebastian Gheith Associate Counsel 169030 0 0 0 0 0 12250 0 55728 0 237008 0 0 0 COMPENSATION PART I, LINE 4 CHIEF EXECUTIVE OFFICER, KEVIN FROST, PARTICIPATED IN A SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN. IN CALENDAR YEAR 2018, AMFAR CONTRIBUTED $55,637 INTO MR. FROST'S NON-QUALIFIED RETIREMENT PLAN. THIS AMOUNT IS NOT REPORTED IN SCHEDULE J, PART II, COLUMN (C) BECAUSE THE CONTRIBUTED AMOUNT WAS DISTRIBUTED TO MR. FROST WITHIN THE SAME CALENDAR YEAR. INCLUDED IN SCHEDULE J COLUMN (B)(III) IS MR. FROST'S 2018 EMPLOYER-FUNDED 457(F) CONTRIBUTION OF $55,637. X 6 63158 sales price false true false FORM 990, SCHEDULE M, LINE 31 TO THE EXTENT THAT AMFAR RECEIVES NON-STANDARD CONTRIBUTIONS, THE ORGANIZATION'S POLICY IS TO LIQUIDATE THOSE ITEMS INTO CASH FOR EVENTUAL USE IN SUPPORT OF THE ORGANIZATION'S MISSION. PROGRAM SERVICE ACCOMPLISHMENTS (1) LINE 4A: RESEARCH: AMFAR SUPPORTS RESEARCH PROJECTS THAT EXPLORE NOVEL APPROACHES TO SCIENTIFICALLY SOUND BUT UNTESTED HYPOTHESES IN ALL AREAS OF RESEARCH ON HIV/AIDS, FUNDING GOAL-ORIENTED STUDIES THAT OFTEN LACK THE PRELIMINARY DATA REQUIRED FOR SUPPORT FROM TRADITIONAL GRANT MAKERS. THE FOUNDATION PLAYS A VITAL ROLE IN HIV/AIDS RESEARCH, IDENTIFYING CRITICAL GAPS IN KNOWLEDGE AND PROVIDING ESSENTIAL SEED MONEY THAT ENABLES GRANTEES AND FELLOWS TO TEST THE MERITS OF NEW CONCEPTS OR TECHNOLOGIES THAT SUBSEQUENTLY CAN BE VALIDATED THROUGH LARGE-SCALE STUDIES, SUCH AS THOSE FUNDED BY THE U.S. NATIONAL INSTITUTES OF HEALTH. AMFAR FELLOWSHIPS ALLOW TALENTED YOUNG RESEARCHERS TO CONDUCT ORIGINAL INVESTIGATIONS UNDER THE GUIDANCE OF EXPERIENCED SCIENTISTS, HELPING TO ENSURE THE LONG-TERM VITALITY OF AIDS RESEARCH. NEW GRANTS AND FELLOWSHIPS GRANTS AND FELLOWSHIPS ARE AWARDED THROUGH A RIGOROUS PROCESS OF PEER REVIEW BY A TEAM OF INDEPENDENT HIV/AIDS EXPERTS DRAWN LARGELY FROM THE VOLUNTEER SCIENTISTS ON AMFARS SCIENTIFIC ADVISORY COMMITTEE. GUIDED BY ITS SCIENTIFIC ADVISORS AND WITH THE APPROVAL OF ITS BOARD OF TRUSTEES, AMFAR PURSUES A STRATEGIC RESEARCH PLAN THAT FOCUSES ON THE PURSUIT OF A CURE FOR HIV. COUNTDOWN TO A CURE FOR AIDS IN 2015, AMFAR ANNOUNCED AN INVESTMENT STRATEGY OF UP TO $100 MILLION TO SUPPORT ITS COUNTDOWN TO A CURE FOR AIDS INITIATIVE, WHICH IS AIMED AT DEVELOPING THE SCIENTIFIC BASIS FOR A CURE BY THE END OF 2020. THE STRATEGY REPRESENTS AN UNPRECEDENTED EXPANSION OF AMFARS GRANT MAKING AND IS DESIGNED TO PROVIDE SUPPORT TO ANY SCIENTIST OR TEAM OF INVESTIGATORS FOR ANY RESEARCH IDEA WITH THE POTENTIAL TO ADVANCE THE SEARCH FOR A CURE, AT ANY STAGE OF ITS DEVELOPMENT. IT IS STRUCTURED TO PROVIDE SUSTAINED SUPPORT FOR A WIDE RANGE OF STUDIES THAT ADVANCE BOTH EMERGING AND ESTABLISHED IDEAS. THE STRATEGY COMPRISES THE FOLLOWING COMPONENTS: - AMFAR INSTITUTE FOR HIV CURE RESEARCH ESTABLISHED IN 2015 WITH A $20 MILLION GRANT OVER FIVE YEARS TO THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE INSTITUTE IS THE CORNERSTONE OF AMFARS CURE RESEARCH. - INNOVATION GRANTS THESE TWO-YEAR AWARDS OF UP TO $200,000 EACH ENABLE RESEARCHERS TO TEST INNOVATIVE IDEAS SUPPORTED BY LIMITED PRELIMINARY DATA. - IMPACT GRANTS THESE GRANTS OF UP TO $2 MILLION EACH OVER FOUR YEARS SUPPORT THE IN-DEPTH DEVELOPMENT OF CONCEPTS ALREADY UNDERPINNED BY PRELIMINARY DATA SHOWING GENUINE POTENTIAL FOR ACHIEVING A CURE. - INVESTMENT GRANTS AIMED AT RECRUITING THE EXPERIENCE AND EXPERTISE OF SCIENTISTS FROM OUTSIDE THE FIELD OF HIV, THESE $1 MILLION GRANTS ARE AWARDED OVER A FOUR-YEAR PERIOD. GRANTEES MAY HAVE EXPERTISE IN FIELDS SUCH AS CANCER, NEUROSCIENCE, OR INFLAMMATORY DISEASE THAT CAN DIRECTLY INFORM EFFORTS TO CURE HIV. - ARCHE LAUNCHED IN 2010, THE AMFAR RESEARCH CONSORTIUM ON HIV ERADICATION, OR ARCHE, SUPPORTS COLLABORATIVE TEAMS OF SCIENTISTS IN THE U.S. AND AROUND THE WORLD WORKING ON A RANGE OF HIV CURE STRATEGIES. - OPPORTUNITY FUND THIS FUNDING MECHANISM ENABLES AMFAR TO RESPOND QUICKLY TO EMERGING AND UNFORESEEN RESEARCH OPPORTUNITIES. SINCE LAUNCHING THE COUNTDOWN TO A CURE FOR AIDS INITIATIVE, AMFAR HAS AWARDED 79 COUNTDOWN GRANTS TOTALING MORE THAN $48 MILLION TO SUPPORT RESEARCH CONDUCTED BY 277 SCIENTISTS WORKING AT 95 INSTITUTIONS IN 15 COUNTRIES. IMPACT GRANTS IN SEPTEMBER 2018, AMFAR AWARDED GRANTS TOTALING $828,000 TO ADVANCE TWO CRITICAL AREAS OF HIV CURE RESEARCH. FIVE GRANTS ARE SUPPORTING A RANGE OF EFFORTS TO UNDERSTAND THE MECHANISMS AND PREDICTORS OF POST-TREATMENT CONTROL, WHEREBY A SMALL NUMBER OF INDIVIDUALS ARE ABLE TO CONTROL THEIR HIV AFTER STOPPING TREATMENT. THREE ADDITIONAL GRANTEES ARE STUDYING HIV-POSITIVE POPULATIONS IN LOW- AND MIDDLE-INCOME COUNTRIES TO LOOK FOR DIFFERENCES IN HOW THE PERSISTENT VIRAL RESERVOIR-THE PRINCIPAL BARRIER TO A CUR-FORMS AND CHANGES OVER TIME. IN A COHORT OF POST-TREATMENT CONTROLLERS FROM ONE OF THE LARGEST HIV CLINICAL TRIAL NETWORKS IN THE WORLD, DR. JONATHAN LI OF BRIGHAM AND WOMEN'S HOSPITAL IN BOSTON IS USING NEXT-GENERATION GENOMIC SEQUENCING TO INVESTIGATE WHETHER CHARACTERISTICS OF THE VIRUS OR IMMUNOLOGIC RESPONSES CAN PREDICT POST-TREATMENT CONTROL. ANOTHER GRANTEE, DR. GODWIN NCHINDA, A RESEARCHER IN YAOUNDE, CAMEROON, HAS IDENTIFIED A COHORT OF WOMEN WHO RECEIVED ANTIRETROVIRAL THERAPY (ART) DURING PREGNANCY AND CONTINUE TO CONTROL THEIR VIRUS DESPITE DISCONTINUING TREATMENT AFTER GIVING BIRTH. HE IS STUDYING THIS GROUP TO DETERMINE THE CAUSES OF THEIR VIRAL CONTROL. THE MAJORITY OF WHAT IS KNOWN ABOUT HIV COMES FROM RESEARCH DONE IN HIGH-INCOME COUNTRIES, WHERE HIV SUBTYPE B PREDOMINATES. HOWEVER, SUBTYPE B ACCOUNTS FOR JUST 12% OF GLOBAL HIV INFECTIONS. DR. EDWARD KANKAKA OF THE RAKAI HEALTH SCIENCES PROGRAM IN KAMPALA, UGANDA, HAS SHOWN THAT NON-B HIV-POSITIVE UGANDANS HAD A SMALLER RESERVOIR OF PERSISTENT VIRUS COMPARED TO PEOPLE INFECTED WITH SUBTYPE B. DR. KANKAKA IS EXPANDING THESE STUDIES TO DETERMINE WHETHER FORMATION AND MAINTENANCE OF THE RESERVOIR DIFFER IN THESE POPULATIONS. IN DURBAN, SOUTH AFRICA, DR. ALEX SIGAL IS EXAMINING THE INFLUENCE OF TUBERCULOSIS-A COMMON CO-INFECTION IN LOW- AND MIDDLE-INCOME COUNTRIES-ON THE HIV RESERVOIR. HE IS EXPLORING WHETHER THE IMMUNE RESPONSE TO TB ITSELF ALTERS HIV REACTIVATION-A KEY COMPONENT OF THE "SHOCK AND KILL" APPROACH TO CURING HIV. THE REMAINING GRANTEES ARE DR. MOHAMED ABDEL-MOHSEN OF THE WISTAR INSTITUTE, PHILADELPHIA, PA; DR. JOHN FRATER OF OXFORD UNIVERSITY, UK; DR. REENA RAJASURIAR OF THE UNIVERSITY OF MALAYA, KUALA LUMPUR, MALAYSIA; AND DR. RUI WANG OF HARVARD PILGRIM HEALTHCARE INSTITUTE, WELLESLEY, MA. INVESTMENT GRANTS IN FEBRUARY 2019, AMFAR ANNOUNCED NEW FUNDING TO RESEARCHERS USING CUTTING-EDGE TECHNOLOGY TO ADDRESS THE MAIN BARRIER TO AN HIV CURE: THE PERSISTENT RESERVOIRS OF VIRUS NOT CLEARED BY ART. TOTALING $800,000, THIS NEW ROUND OF INVESTMENT GRANTS LAUNCHED THE CRITICAL THIRD PHASE OF A RESEARCH PROJECTS BEGUN IN 2017. IN THE FIRST TWO PHASES OF HER STUDY, DR. HUI ZHANG OF JOHNS HOPKINS UNIVERSITY USED MASS SPECTROMETRY TO SCAN THE SURFACE OF HUMAN CELLS FOR PROTEINS-BIOMARKERS-THAT DISCRIMINATE BETWEEN LATENTLY INFECTED AND UNINFECTED CELLS. AFTER SCANNING A VARIETY OF CELL LINES, SHE IDENTIFIED 17 POTENTIAL TARGETS. IN PHASE THREE, DR. ZHANG IS TEAMING UP WITH HIV SCIENTIST DR. WEIMING YANG, ALSO OF JOHNS HOPKINS UNIVERSITY, TO DETERMINE IN A PRECLINICAL STUDY WHETHER SPECIFICALLY KILLING CELLS DISPLAYING ANY OF THESE 17 PROTEINS WILL ELIMINATE THE LATENT RESERVOIR. ARCHE (AMFAR RESEARCH CONSORTIUM ON HIV ERADICATION) IN SEPTEMBER 2018, AMFAR AWARDED $800,000 IN NEW FUNDING TO SIX TEAMS OF RESEARCHERS DEVELOPING AN AMBITIOUS GENE THERAPY-BASED APPROACH TO CURING HIV. THE AWARD LAUNCHED A CRITICAL NEW PHASE IN A STUDY INITIATED IN 2017. IN A THREE-PRONGED ATTACK ON THE HIV RESERVOIR, THE RESEARCHERS ARE EMPLOYING BROADLY NEUTRALIZING ANTIBODIES, CAR STEM CELLS-CELLS GENETICALLY REPROGRAMMED TO RECOGNIZE AND ATTACK INFECTED CELLS-AND MOLECULAR SCISSORS TARGETING THE VIRUS. THE GRANT WAS SUPPORTED IN PART BY THE BILL AND MELINDA GATES FOUNDATION. THE INVESTIGATORS ARE: DR. HILDEGARD BNING OF HANNOVER MEDICAL SCHOOL, GERMANY; DR. KEITH JEROME OF THE UNIVERSITY OF WASHINGTON, SEATTLE; DR. HANS-PETER KIEM OF FRED HUTCHINSON CANCER RESEARCH CENTER, SEATTLE; DR. SCOTT KITCHEN OF UCLA; DR. YASUHIRO TAKEUCHI OF UNIVERSITY COLLEGE LONDON; DR. DREW WEISSMAN OF UNIVERSITY OF PENNSYLVANIA IN PHILADELPHIA; AND DR. RICHARD WYATT OF THE SCRIPPS RESEARCH INSTITUTE IN LA JOLLA, CA. IN JUNE 2019, AMFAR AWARDED $1.16 MILLION IN ARCHE GRANTS FOR A PAIR OF INNOVATIVE RESEARCH STUDIES PURSUING DIFFERENT ANGLES TO ATTACK HIV. DR. KEITH JEROME OF THE UNIVERSITY OF WASHINGTON, SEATTLE, WAS AWARDED $344,000 FOR A PROJECT THAT AIMS TO ADVANCE A GENE THERAPY STRATEGY FOR CURING HIV. GENE THERAPY IS VERY PROMISING, BUT IT CARRIES RISKS AND IT IS EXTREMELY EXPENSIVE. AMFARS ARCHE-GT CONSORTIUM PLANS TO REDUCE COSTS BY DEVELOPING IN VIVO GENE THERAPY IN WHICH THE GENE-ENGINEERING TOOLS ARE INJECTED DIRECTLY INTO THE PATIENT USING VECTORS, WHICH FUNCTION AS "TROJAN HORSES". DR. JEROMES TEAM PLANS TO COMPARE WHICH OF 11 VECTORS DELIVERS THE GENE-EDITING TOOLS MOST EFFECTIVELY TO THE VARIOUS SPECIFIC TISSUES THAT ARE BEING TARGETED. THESE LEAD CANDIDATES WILL THEN BE USED IN FUTURE STUDIES OF COMBINATION IN VIVO GENE THERAPY INTERVENTIONS. AND DR. JONATHAN LI OF BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, WAS AWARDED $815,000 FOR A PROJECT STUDYING POST-TREATMENT CONTROL OF THE VIRUS (SEE IMPACT GRANTS ABOVE). DR. LI AND HIS TEAM HAVE ASSEMBLED AN IMPRESSIVE COHORT OF POST-TREATMENT CONTROLLERS-INDIVIDUALS WHO EXHIBIT THE RARE ABILITY TO CONTROL THE VIRUS AFTER STOPPING ART-FROM ONE OF THE LARGEST HIV CLINICAL TRIAL NETWORKS GLOBALLY. THE RESEARCH TEAM IS GATHERING AND ANALYZING SAMPLES FROM THIS MULTINATIONAL POST-TREATMENT CONTROL COHORT AND WILL BE ABLE TO EMPLOY CUTTING-EDGE TOOLS TO INVESTIGATE WHETHER CHARACTERISTICS OF THE VIRUS OR IMMUNOLOGIC RESPONSES CAN PREDICT POST-TREATMENT CONTROL. DISCOVERING WHAT LEADS TO POST-TREATMENT CONTROL IN SOME PEOPLE COULD HELP TO ACHIEVE DURABLE ART-FREE CONTROL IN ALL PEOPLE LIVING WITH HIV. MATHILDE KRIM FELLOWSHIPS IN SEPTEMBER 2018, AMFAR ANNOUNCED THE RECIPIENT OF THE 2018 MATHILDE KRIM FELLOWSHIP IN BASIC BIOMEDICAL RESEARCH: DR. YEN-TING LAI OF THE VACCINE RESEARCH CENTER/NATIONAL INSTITUTES OF HEALTH IN BETHESDA, MD. THE 2019 KRIM FELLOWS, DR. MAOLIN LU OF YALE UNIVERSITY IN NEW HAVEN, CT, AND DR. SHAHEED ABDULHAQQ, OF OREGON HEALTH AND SCIENCE UNIVERSITY IN PORTLAND, OR, WERE ANNOUNCED IN SEPTEMBER 2019. THE KRIM FELLOWSHIPS SUPPORT BRIGHT YOUNG SCIENTISTS ADVANCING INNOVATIVE SOLUTIONS TO HIV/AIDS. EACH FELLOW IS AWARDED APPROXIMATELY $150,000 OVER TWO YEARS. PROGRAM SERVICE ACCOMPLISHMENTS (1) CONT. PUBLISHED RESEARCH RESEARCH STUDIES MAKE THE GREATEST IMPACT ON THE HIV FIELD AND ON THE BROADER SCIENTIFIC COMMUNITY WHEN THEY ARE PUBLISHED IN SCIENTIFIC JOURNALS. IN FY2019, 53 SCIENTIFIC PUBLICATIONS RESULTED FROM AMFAR-FUNDED RESEARCH. EXAMPLES INCLUDE: THE "LONDON PATIENT" IS POTENTIALLY CURED FOLLOWING A STEM CELL TRANSPLANT THE "BERLIN PATIENT"-TIMOTHY BROWN-WAS THE FIRST PERSON KNOWN TO HAVE BEEN CURED OF HIV. DIAGNOSED WITH LEUKEMIA, HE RECEIVED A STEM CELL TRANSPLANT FROM A DONOR WITH A RARE GENETIC MUTATION CONFERRING RESISTANCE TO HIV INFECTION. AMFAR'S ICISTEM CONSORTIUM WAS ESTABLISHED TO REPLICATE AND IDENTIFY THE MECHANISMS UNDERLYING HIS CURE, AND HAS ASSEMBLED THE LARGEST COHORT OF PATIENTS WITH HIV WHO HAVE RECEIVED, OR WILL SOON RECEIVE, STEM CELL TRANSPLANTS. IN THE MARCH 2019 ISSUE OF NATURE, DR. RAVI GUPTA AND COLLEAGUES REPORTED ON THE "LONDON PATIENT," THE SECOND INDIVIDUAL POTENTIALLY CURED FOLLOWING A STEM CELL TRANSPLANT. THIS CASE-ALONG WITH THE "DSSELDORF PATIENT," A THIRD POTENTIALLY CURED INDIVIDUAL-IS PROVIDING CRITICAL NEW DATA TO COMPARE WITH THE "BERLIN PATIENT." THE ABILITY TO CONTROL HIV WITHOUT ANTIRETROVIRAL THERAPY RUNS IN FAMILIES CCR5, THE PRIMARY RECEPTOR ENABLING HIV TO INFECT CELLS, IS KNOWN FOR ITS ROLE IN THE CURE OF THE "BERLIN PATIENT" FOLLOWING A STEM CELL TRANSPLANT WITH DONOR CELLS BEARING A MUTATED CCR5 PROTEIN. IN THE APRIL 2019 ISSUE OF ELIFE, DR. STEVEN DEEKS AND COLLEAGUES FOUND ANOTHER WAY THAT CCR5 IS CONNECTED TO THE ABILITY TO CONTROL HIV WITHOUT ART. THE RESEARCHERS STUDIED 131 INDIVIDUALS-ABOUT HALF ELITE AND HALF VIREMIC CONTROLLERS, ABLE TO NATURALLY MAINTAIN VIRAL LOADS OF LESS THAN 50 OR 2000 COPIES, RESPECTIVELY-SOME OF WHOM HAVE BEEN INFECTED SINCE 1980. THEY DISCOVERED THAT CONTROL WAS RELATED TO A NATURAL AND PARTIAL RESISTANCE TO INFECTION IN CONTROLLERS AND NONCONTROLLERS. FURTHER ANALYSIS SHOWED THAT CONTROLLERS HAD LESS CCR5 PRESENT ON THEIR CELLS THAN NONCONTROLLERS, AND THEIR CELLS WERE LESS PERMISSIVE TO HIV INFECTION. FURTHERMORE, NATURAL RESISTANCE TO HIV WAS SHOWN TO BE INHERITED, AS MULTIPLE GENERATIONS OF FAMILY MEMBERS, MALE AND FEMALE, FROM ONE OF THE VIREMIC CONTROLLERS HAD A SIMILAR PROFILE OF LOWERED CCR5. STUDYING HOW AND UNDER WHAT CIRCUMSTANCES THESE CONTROLLERS MAKE LOWER LEVELS OF CCR5 MAY LEAD TO NEW DISCOVERIES THAT COULD INFORM INTERVENTIONS FOR A FUNCTIONAL CURE. IDENTIFYING A BIOMARKER FOR THE 'ACTIVE' HIV RESERVOIR IN THE MAY 2019 ISSUE OF PATHOGENS AND IMMUNITY, DRS. TIMOTHY HENRICH AND PETER HUNT, BOTH AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, REPORTED ON EFFORTS TO SEE WHETHER THE PROTEIN CD32-PREVIOUSLY SHOWN TO BE A BIOMARKER FOR HIV ACTIVITY IN BLOOD CELLS-MIGHT ALSO DENOTE ACTIVITY IN THE TISSUES. THE RESEARCHERS EXAMINED GUT BIOPSIES FROM FOUR STUDY PARTICIPANTS WHOSE MEDICATION HAD REDUCED THE HIV IN THEIR BLOOD TO UNDETECTABLE LEVELS. THEY NOTED THAT ABOUT FOUR IN EVERY 100,000 CELLS IN THE TISSUE HAD STARTED ACTIVITY OF THE PROVIRUS, MEANING THEY HAD BEGUN THE FIRST STEPS TOWARDS PRODUCING NEW VIRUSES. THE STUDY CONFIRMED THAT CD32 MAY NOT BE A BIOMARKER OF THE LATENT RESERVOIR, BUT MAY BE A BIOMARKER OF WHAT MIGHT BE CALLED THE "ACTIVE RESERVOIR"-PERSISTENT VIRUS THAT IS PROBABLY FIRST TO RE-SEED INFECTION WHEN ART IS STOPPED. THINKING ON THE NATURE OF THE RESERVOIR IS EVOLVING TO INCLUDE NOT ONLY LATENT, BUT ALSO ACTIVE RESERVOIR, AND BOTH ARE MAJOR BARRIERS TO A CURE. FINDING A WAY TO DIFFERENTIATE CELLS HARBORING ACTIVE RESERVOIR FROM HEALTHY, UNINFECTED CELLS WOULD BE AN IMPORTANT ADVANCE. HIV CURE SUMMIT IN DECEMBER 2018, AMFAR HELD ITS FIFTH ANNUAL HIV CURE SUMMIT AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (UCSF), WHERE THE AMFAR INSTITUTE FOR HIV CURE RESEARCH IS BASED. LEADING AMFAR-FUNDED CURE RESEARCHERS DETAILED THEIR PROGRESS AND DISCUSSED THE SCIENTIFIC CHALLENGES THAT CONTINUE TO STAND IN THE WAY OF A CURE. MUCH OF THE DISCUSSION CENTERED ON ANALYTIC TREATMENT INTERRUPTION. THE ONLY MEANS CURRENTLY AVAILABLE FOR PROVING THAT A PERSON HAS BEEN CURED IS TO REMOVE ANTIRETROVIRAL THERAPY UNDER CLOSELY CONTROLLED AND MONITORED CONDITIONS. DR. ROWENA JOHNSTON, AMFAR VICE PRESIDENT AND DIRECTOR OF RESEARCH, ELUCIDATED THE TWO TYPES OF CURE THAT RESEARCHERS ARE PURSUING: ERADICATION AND POST-TREATMENT CONTROL. IN ERADICATION, AN INDIVIDUAL COMPLETELY CLEARS HIV FROM HIS OR HER BODY; AND IN POST-TREATMENT CONTROL SOME VIRUS REMAINS, BUT THE IMMUNE SYSTEM CAN CONTROL IT WITHOUT ART. DR. STEVEN DEEKS, A PROFESSOR OF MEDICINE AT UCSF AND A LEAD INVESTIGATOR AT THE AMFAR INSTITUTE, EXPLAINED THE COMPLEX CLINICAL STUDY HE IS ABOUT TO EMBARK ON. IN THE STUDY, DR. DEEKS AND HIS TEAM WILL ADMINISTER A SERIES OF THERAPEUTIC VACCINES, BROADLY NEUTRALIZING ANTIBODIES, AND AN AGENT TO SHOCK THE VIRUS OUT OF ITS HIDING PLACES. THE SUMMIT ALSO FEATURED A RANGE OF PERSPECTIVES FROM MEMBERS OF THE COMMUNITY ADVISORY BOARD FOR THE AMFAR INSTITUTE AND OTHER COMMUNITY LEADERS. THINK TANKS CONSISTENT WITH AMFARS COMMITMENT TO INVESTIGATE EVERY AVENUE THAT MAY LEAD TO A CURE, THE FOUNDATION REGULARLY HOSTS THINK TANKS THAT BRING TOGETHER LEADING INVESTIGATORS IN VARIOUS FIELDS. IN MARCH 2019, AMFAR HOSTED A THINK TANK ON GENE THERAPY. EXPERTS GATHERED TO DISCUSS CUTTING-EDGE APPROACHES TO CURING HIV THAT AMFAR COULD PURSUE THROUGH ITS GENE THERAPY RESEARCH INITIATIVE, ARCHE-GT. IN MAY 2019, MEMBERS OF AMFARS ICISTEM CONSORTIUM OF EUROPEAN RESEARCHERS THAT AIMS TO REPLICATE THE CASE OF "THE BERLIN PATIENT" GATHERED FOR A THINK TANK IN DUBLIN, IRELAND. ICISTEM WAS CREATED AND IS FUNDED BY AMFAR THROUGH ITS COUNTDOWN TO A CURE FOR AIDS INITIATIVE. AND IN AUGUST 2019, AMFAR HOSTED A THINK TANK IN NEW YORK CITY ON THE CCR5 RECEPTOR AS A TARGET IN CURE RESEARCH. THE RESEARCHERS DISCUSSED WAYS TO USE CCR5 TO DEVELOP A MORE GENERALIZABLE CURE THAN ONE INVOLVING RISKY AND COSTLY STEM CELL TRANSPLANTS. PROGRAM SERVICE ACCOMPLISHMENTS (2) LINE 4B: TREAT ASIA: AMFARS TREAT ASIA (THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING IN ASIA) PROGRAM IS A NETWORK OF HOSPITALS, CLINICS, AND RESEARCH INSTITUTIONS WORKING WITH CIVIL SOCIETY TO ENSURE THE SAFE AND EFFECTIVE DELIVERY OF TREATMENTS FOR HIV AND ITS CO-INFECTIONS TO ADULTS AND CHILDREN ACROSS THE ASIA-PACIFIC THROUGH RESEARCH, EDUCATION, AND ADVOCACY OF EVIDENCE-BASED HIV-RELATED POLICIES. THE TREAT ASIA NETWORK ENCOMPASSES 21 ADULT AND 20 PEDIATRIC SITES THROUGHOUT THE REGION, WHICH COLLABORATE ON A VARIETY OF PROJECTS. TREAT ASIA SCIENTISTS PRODUCED 38 PUBLICATIONS IN PEER-REVIEWED MEDICAL JOURNALS IN 2019. INTERNATIONAL AIDS DATABASE TREAT ASIA MANAGES THE ASIA-PACIFIC SECTION OF THE INTERNATIONAL EPIDEMIOLOGY DATABASES TO EVALUATE AIDS (IEDEA), A GLOBAL COLLABORATION ESTABLISHED BY THE U.S. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES. IN FY2019, THE IEDEA CONSORTIUM COMPLETED STAY (STUDY OF TRANSITIONING ASIAN YOUTH), WHICH AIMS TO DOCUMENT THE EXPERIENCE OF HIV-POSITIVE YOUNG ADULTS WHO ARE TRANSITIONING FROM PEDIATRIC TO ADULT CARE. TREAT ASIA HIV OBSERVATIONAL DATABASE (TAHOD) TREAT ASIA PIONEERED THE REGIONS FIRST ADULT OBSERVATIONAL DATABASE FOR HIV/AIDS, WHICH NOW INCLUDES ANONYMOUS DATA FROM NEARLY 10,000 PATIENTS AT 21 CLINICAL SITES IN 12 COUNTRIES. THE INFORMATION GATHERED IN THE DATABASE INFORMS THE DEVELOPMENT OF MORE EFFECTIVE RESEARCH AND TREATMENT PROGRAMS AND HELPS DEFINE TREATMENT STANDARDS SPECIFIC TO HIV/AIDS IN ASIA. TAHOD LOW-INTENSITY TRANSFER LAUNCHED IN 2014, TAHOD LOW-INTENSITY TRANSFER (TAHOD-LITE) CONTAINS DATA FROM OVER 37,000 HIV-POSITIVE PATIENTS ACROSS TEN TREAT ASIA NETWORK SITES. AS AN EXTENSION OF TAHOD, TAHOD-LITE AIMS TO INCREASE THE SCOPE OF ADULT DATA COLLECTION BY GATHERING A SUBSET OF CORE VARIABLES FROM THE ENTIRE COHORT OF HIV-INFECTED PATIENTS WHO HAVE SOUGHT CARE AT SELECTED TAHOD SITES. TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE THE TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TAPHOD) IS A REGIONAL PEDIATRIC HIV STUDY SET UP BY TREAT ASIA IN 2006. IT WAS MODELED AFTER THE ADULT DATABASE AND INCLUDES DATA FROM MORE THAN 6,400 CHILDREN AND ADOLESCENTS AT 17 CLINICAL SITES IN CAMBODIA, INDIA, INDONESIA, MALAYSIA, THAILAND, AND VIETNAM. INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCH IN MAY 2019, THE U.S. NATIONAL INSTITUTES OF HEALTH AWARDED A FIVE-YEAR, $1.4 MILLION GRANT TO TREAT ASIA AND COLUMBIA UNIVERSITY TO ESTABLISH AN INNOVATIVE PLATFORM FOR INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCH IN THE ASIA-PACIFIC REGION. THE OBJECTIVE OF THE CHIMERA PROGRAM (CAPACITY DEVELOPMENT FOR HIV AND MENTAL HEALTH RESEARCH IN ASIA) IS TO ADDRESS THE DUAL AND INTERLINKED BURDENS OF HIV AND MENTAL HEALTH. CO-LED BY PRINCIPAL INVESTIGATORS DR. ANNETTE SOHN, AMFAR VICE PRESIDENT AND DIRECTOR OF TREAT ASIA, AND DR. MILTON WAINBERG, PROFESSOR OF CLINICAL PSYCHIATRY AT COLUMBIA UNIVERSITY AND THE NEW YORK STATE PSYCHIATRIC INSTITUTE, THE PROGRAM AIMS TO BUILD A TEAM WITHIN THE ASIA-PACIFIC WITH THE CAPACITY TO LEAD REGIONAL HIV-MENTAL HEALTH-IMPLEMENTATION SCIENCE RESEARCH THAT WILL INFORM PUBLIC HEALTH POLICY AND IMPROVE THE QUALITY OF CLINICAL CARE FOR PEOPLE LIVING WITH HIV. THE PROGRAM IS NESTED WITHIN THE IEDEA (SEE ABOVE) ASIA-PACIFIC REGIONAL RESEARCH NETWORK THAT TREAT ASIA DIRECTS. CHIMERA WILL CREATE THE OPPORTUNITY TO BRING TOGETHER STELLAR TRAINING FACULTY FROM ACADEMIC CENTERS AND PUBLIC HEALTH AND DEVELOPMENT AGENCIES WITHIN THE REGION AND ACROSS THE WORLD, AND WILL BUILD ON EXISTING NIH-FUNDED MENTAL HEALTH RESEARCH BEING CONDUCTED THROUGH IEDEA ASIA-PACIFIC. EMPOWERING YOUTH ADVOCATES IN DECEMBER 2018, TREAT ASIAS YOUTH ACATA-ASIA COMMUNITY FOR AIDS TREATMENT AND ADVOCACY-HELD A WORKSHOP IN BANGKOK. FOCUSED ON MODELS OF SERVICE DELIVERY FOR KEY POPULATIONS, THE WORKSHOP INCLUDED SITE VISITS TO COMMUNITY-BASED OR KEY POPULATION-FRIENDLY HIV SERVICE PROVIDERS IN BANGKOK. EXPANDING ACCESS TO HIV TREATMENT IN 2018, THE WORLD HEALTH ORGANIZATION (WHO) RECOMMENDED DOLUTEGRAVIR (DTG)-BASED REGIMENS AS THE PREFERRED FIRST-LINE HIV TREATMENT FOR ADULTS AND ADOLESCENTS. BUT IN THE ASIA-PACIFIC REGION, ACCESS TO DTG-BASED REGIMENS REMAINS SEVERELY LIMITED. TO ACCELERATE DTG SCALE-UP IN THE REGION, TREAT ASIA AND THE CLINTON HEALTH ACCESS INITIATIVE ORGANIZED A WORKSHOP IN BANGKOK IN MARCH 2019 TO HELP NETWORKS OF PEOPLE LIVING WITH HIV AND OTHER TREATMENT ACCESS ADVOCATES BETTER UNDERSTAND ISSUES AROUND DTG ACCESS AND USE, AND COORDINATE FUTURE ADVOCACY EFFORTS. ATTENDED BY 25 PARTICIPANTS FROM NINE ASIAN COUNTRIES, THE WORKSHOP BUILT UPON EARLIER COLLABORATIVE EFFORTS WITH THE WHO SOUTH EAST ASIA AND WESTERN PACIFIC REGIONAL OFFICES TO ENHANCE ACCESS TO NEWER HIV AND HEPATITIS C MEDICATIONS. IN APRIL 2019, GITEN KHWAIRAKPAM, TREAT ASIAS PROJECT MANAGER FOR COMMUNITY AND POLICY, LED A TRAINING IN BANGKOK FOR REGIONAL COMMUNITY ADVOCATES AROUND THE USE OF DTG. AND THE FOLLOWING MONTH, TREAT ASIA CO-ORGANIZED A WEBINAR WITH THE WHO WESTERN PACIFIC OFFICE AROUND THE USE OF DTG AND ACCESS ISSUES IN THE REGION. HELPING ADOLESCENTS TRANSITION TO ADULT CARE THERE ARE INCREASINGLY LARGE NUMBERS OF YOUNG ADULTS IN THE ASIA-PACIFIC REGION WITH RECENTLY ACQUIRED INFECTIONS. IN 2017, 30% OF NEW HIV INFECTIONS IN THE ASIA-PACIFIC OCCURRED IN PEOPLE AGED 15-24 YEARS. CONTINUING ITS COMMITMENT TO HELPING ADOLESCENTS TRANSITION TO ADULT CARE, IN JANUARY 2019 TREAT ASIA HELD A THINK TANK ON YOUNG ADULT COHORT RESEARCH TO EXPLORE OPPORTUNITIES FOR A NEW COHORT STUDY FOCUSING ON YOUNG ADULTS. ADVOCATING FOR CO-INFECTION TREATMENT ACCESS IN JUNE 2019, TREAT ASIA HELD ITS ANNUAL REGIONAL ADVOCACY MEETING ON HEPATITIS C, HIV, AND TUBERCULOSIS TREATMENT IN BANGKOK, WITH CIVIL SOCIETY ORGANIZATIONS, CLINICAL CARE PROFESSIONALS, AND INTELLECTUAL PROPERTY EXPERTS. DURING THE YEAR, TREAT ASIA ALSO ATTENDED AND PRESENTED AT SEVERAL CONFERENCES ON HEPATITIS C TREATMENT ACCESS AND PARTNERED WITH CIVIL SOCIETY GROUPS AND FUNDERS ON ADVOCACY EFFORTS. PUBLICATIONS TREAT ASIA DIRECTOR DR. ANNETTE SOHN CO-AUTHORED AN OP-ED FOR ASIA-PACIFIC BIOTECH NEWS, TITLED "ASIA-PACIFIC: FALLING BEHIND IN THE FIGHT AGAINST HIV/AIDS." THE OP-ED, COAUTHORED BY A SINGAPOREAN INVESTIGATOR, DISCUSSED THE CURRENT STATE OF THE HIV EPIDEMIC IN ASIA, AND HIGHLIGHTED PRIORITY ISSUES FOR THE REGIONAL RESPONSE. IN JANUARY 2019, TREAT ASIA PRODUCED THE FACT SHEET, WHO GUIDELINES FOR THE SCREENING, CARE, AND TREATMENT OF PERSONS WITH HEPATITIS C INFECTION. THE FACT SHEET SUMMARIZES WHO GUIDELINES (UPDATED, JULY 2018) ON CARE AND TREATMENT OF HEPATITIS C VIRUS INFECTION, WHICH ARE AIMED AT HELPING POLICYMAKERS AND HEALTHCARE PROVIDERS IN LOW- AND MIDDLE-INCOME COUNTRIES ESTABLISH SCREENING, CARE, AND TREATMENT PROGRAMS. AND IN FEBRUARY 2019, TREAT ASIA UPDATED THE BROCHURE, TREAT ASIA: A COOPERATIVE APPROACH TO COMBATING HIV IN ASIA AND THE PACIFIC, WHICH HIGHLIGHTS KEY FACTS AND FIGURES OF THE HIV EPIDEMIC IN THE REGION. THE BROCHURE MAKES THE CASE THAT TREAT ASIAS UNIQUE CAPACITY TO BRING TOGETHER RESEARCHERS, CLINICIANS, ADVOCATES, AND POLICYMAKERS PLAYS AN IMPORTANT ROLE IN THE REGIONS RESPONSE TO HIV/AIDS, AND HAS BECOME A MODEL FOR REGIONAL COLLABORATION. IN ADDITION, TREAT ASIA CONTINUED TO PUBLISH LAY-LANGUAGE ARTICLES ON HIV/AIDS RESEARCH, POLICY, AND COMMUNITY ISSUES FACING THE ASIA-PACIFIC AS A WHOLE. THE ARTICLES AND EDUCATIONAL PIECES APPEAR IN THE TREAT ASIA REPORT, A BIMONTHLY E-NEWSLETTER, AND ON TREAT ASIAS WEBSITE, WWW.TREATASIA.ORG. 18TH ANNUAL NETWORK MEETING THE 2018 TREAT ASIA ANNUAL NETWORK MEETING WAS HELD IN OCTOBER 2018 IN BANGKOK, THAILAND, WHERE MORE THAN 120 ADULT AND PEDIATRIC INVESTIGATORS, DONORS, AND PROGRAM PARTNERS GATHERED TO REVIEW PROGRESS ON THE NETWORKS RESEARCH AGENDA, HEAR ABOUT REGIONAL HIV-RELATED POLICY PRIORITIES, AND PLAN FOR FUTURE INITIATIVES. OTHER CONFERENCES TREAT ASIA STAFF AND NETWORK INVESTIGATORS ATTENDED AND PRESENTED AT SEVERAL REGIONAL AND INTERNATIONAL CONFERENCES ON HIV-RELATED ISSUES. EXAMPLES INCLUDE: IAS 2019 TREAT ASIA HAD A STRONG PRESENCE AT THE 10TH INTERNATIONAL AIDS SOCIETY CONFERENCE ON HIV SCIENCE (IAS 2019) IN MEXICO CITY IN JULY. TREAT ASIA DIRECTOR DR. ANNETTE SOHN CO-CHAIRED A SPECIAL SESSION WITH FORMER IAS PRESIDENT DR. CHRIS BEYRER OF JOHNS HOPKINS UNIVERSITY, CALLED "DATA LEADING THE WAY: DESIGNING RESPONSES BASED ON THE NUMBERS." DR. SOHN WAS ALSO A SESSION CO-CHAIR AT THE INTERNATIONAL WORKSHOP ON HIV PEDIATRICS, WHICH CONVENED IMMEDIATELY BEFORE IAS 2019. GITEN KHWAIRAKPAM, TREAT ASIA'S PROJECT MANAGER FOR COMMUNITY AND POLICY, CO-CHAIRED THE 5TH INTERNATIONAL HIV/VIRAL HEPATITIS CO-INFECTION PRECONFERENCE. PROGRAM SERVICE ACCOMPLISHMENTS (2) CONT. APACC TREAT ASIA WAS ALSO WELL REPRESENTED AT THE FOURTH ASIA PACIFIC AIDS & CO-INFECTIONS CONFERENCE (APACC), HELD IN JUNE 2019 IN HONG KONG. SEVERAL JUNIOR INVESTIGATORS AND PH.D. STUDENTS AFFILIATED WITH THE TREAT ASIA NETWORK GAVE ORAL AND POSTER PRESENTATIONS AT THE CONFERENCE. APACC IS A REGIONAL-LEVEL HIV RESEARCH CONFERENCE THAT PROVIDES OPPORTUNITIES FOR LOCAL CLINICIANS, STUDENTS, AND RESEARCHERS TO SUBMIT ABSTRACTS FOR PRESENTATION. PROGRAM SERVICE ACCOMPLISHMENTS (3) LINE 4C: PUBLIC INFORMATION: AMFAR SEEKS TO TRANSLATE AND DISSEMINATE INFORMATION ON IMPORTANT HIV-RELATED RESEARCH, TREATMENT, PREVENTION, AND POLICY ISSUES FOR DIVERSE AUDIENCES AND TO INCREASE AWARENESS AND KNOWLEDGE OF THE PANDEMIC. AMFAR PUBLISHES A WIDE RANGE OF EDUCATIONAL MATERIALS, MAINTAINS AN INFORMATIVE WEBSITE, AND ENGAGES RESPECTED PUBLIC FIGURES, HIV/AIDS SCIENTISTS, AND POLICYMAKERS IN COMMUNICATING THE NEED FOR CONTINUED RESEARCH TO DEVELOP NEW METHODS OF PREVENTION, TREATMENT, AND, ULTIMATELY, A CURE FOR HIV. EDUCATIONAL MATERIALS AMFAR PRODUCES A RANGE OF PERIODICALS IN BOTH PRINT AND ELECTRONIC FORMATS, INCLUDING ITS NEWSLETTER INNOVATIONS, PUBLISHED TWICE A YEAR AND DISTRIBUTED TO MORE THAN 40,000 PEOPLE; THE TREAT ASIA REPORT, AN EMAIL NEWSLETTER DISTRIBUTED SIX TIMES A YEAR TO MORE THAN 4,000 READERS IN THE INTERNATIONAL HEALTH COMMUNITY; AND A MONTHLY E-MAIL NEWSLETTER DISTRIBUTED TO APPROXIMATELY 11,000 PEOPLE. IN 2019, AMFAR REMOVED OUTDATED ADDRESSES FROM ITS EMAIL LIST AND SIGNIFICANTLY IMPROVED ENGAGEMENT WITH ITS AUDIENCE. THE MONTHLY OPEN RATE INCREASED FROM AN AVERAGE OF ABOUT 10% TO 30%. THE FOUNDATIONS WEBSITES-WWW.AMFAR.ORG AND WWW.CURECOUNTDOWN.ORG-FEATURE NEWS, INTERVIEWS, AND ORIGINAL ARTICLES COVERING HIV RESEARCH, POLICY, THE GLOBAL EPIDEMIC, AND AMFAR PROGRAMS AND ACTIVITIES. THE WEBSITES ATTRACT A COMBINED AVERAGE OF 36,000 VISITORS PER MONTH. AMFAR ALSO CREATES AND DISTRIBUTES REPORTS, PRESS RELEASES, AND UPDATES ON MAJOR HIV/AIDS ISSUES AND CONDUCTS PUBLIC SERVICE ADVERTISING CAMPAIGNS THAT HAVE BEEN INSTRUMENTAL IN EDUCATING POLICYMAKERS, HEALTHCARE PROFESSIONALS, PEOPLE LIVING WITH HIV/AIDS, AND THE PUBLIC. PUBLIC POLICY AMFARS PUBLIC INFORMATION TEAM WORKS CLOSELY WITH THE PUBLIC POLICY OFFICE (SEE ABOVE) TO PRODUCE A WIDE RANGE OF ISSUE BRIEFS, FACTS SHEETS, INFOGRAPHICS, AND REPORTS. IN 2019 IT ALSO WORKED WITH AN ANIMATION STUDIO TO PRODUCE A SHORT FILM SHOWCASING THE FEATURES AND FUNCTIONALITY OF AMFARS OPIOID & HEALTH INDICATORS DATABASE (OPIOID.AMFAR.ORG). EPIC VOICES AMFARS EPIC VOICES, AN ONLINE VIDEO SERIES THAT AIMS TO REENERGIZE THE RESPONSE TO HIV AMONG MILLENNIAL AND LGBTQ COMMUNITIES CONTINUED TO GENERATE SIGNIFICANT PUBLICITY WITH SEVERAL NEW STORIES PUBLISHED IN 2019. LAUNCHED IN 2017, THE GOALS OF THE CAMPAIGN ARE TO: RENEW AWARENESS OF THE PERSISTENT THREAT OF HIV, UNDERSCORE THE URGENT NEED TO SUPPORT HIV RESEARCH, AND SUPPORT AMFARS LEADERSHIP IN THE SEARCH FOR A CURE. AMFAR SPOKE TO HIV ACTIVISTS ACROSS THE COUNTRY AND ASKED THEM TO SHARE THEIR UNIQUE JOURNEYS, THEIR INSIGHTS ON LIVING WITH HIV, AND THE BOLD STEPS THEY HAVE TAKEN IN THE FIGHT AGAINST THE EPIDEMIC. SOCIAL MEDIA AMFAR HAS VIGOROUSLY EXPANDED ITS PRESENCE IN THE SOCIAL MEDIA ARENA, REACHING LARGE NUMBERS OF PEOPLE, INCLUDING A YOUNGER DEMOGRAPHIC THAT IS OFTEN LESS EDUCATED ABOUT HIV AND THE AIDS EPIDEMIC. THE FOUNDATION REGULARLY ADDS CONTENT TO ITS FACEBOOK PAGE, LIVE TWEETS FROM EVENTS, AND POSTS IMAGES ON INSTAGRAM FROM FUNDRAISING AND PROGRAM EVENTS. AMFAR HAS 73,000 LIKES ON FACEBOOK, MORE THAN 43,000 TWITTER FOLLOWERS, AND 164,000 INSTAGRAM FOLLOWERS. MEDIA OUTREACH IN FY2019, AMFAR CONTINUED TO WORK CLOSELY WITH THE MEDIA TO RAISE THE PROFILE OF HIV/AIDS, BOTH DOMESTICALLY AND INTERNATIONALLY, AND TO HELP ENSURE THE ACCURACY OF HIV-RELATED PRESS COVERAGE. ARTICLES AND REPORTS INVOLVING AMFAR-MANY OF WHICH INCLUDED INTERVIEWS WITH STAFF-WERE CARRIED IN NUMEROUS MEDIA OUTLETS, INCLUDING THE NEW YORK TIMES, WIRED, SCIENCE, THE WASHINGTON POST, BANGKOK POST, USA TODAY, U.S. NEWS & WORLD REPORT, PEOPLE, VOX, VOGUE, VANITY FAIR, ESSENCE, BUSTLE, THE ADVOCATE, POZ, CBS NEWS, NBC NEWS, ABC NEWS, FOX NEWS, NPR, ASSOCIATED PRESS, AND REUTERS. CELEBRITY SUPPORT AMFARS PUBLIC AWARENESS EFFORTS ARE GREATLY ENHANCED BY THE COMMITTED SUPPORT OF PUBLIC FIGURES WHO LEND THEIR VOICES AND DONATE THEIR TIME, TALENTS, AND RESOURCES TO HELP SUSTAIN THE FOUNDATIONS MISSION. SUPPORT OF AMFAR BY PROMINENT PUBLIC FIGURES BEGAN WITH THE LATE DAME ELIZABETH TAYLOR, AMFARS FOUNDING INTERNATIONAL CHAIRMAN, AND OTHERS HAVE FOLLOWED IN HER FOOTSTEPS. AMFAR IS PROFOUNDLY GRATEFUL FOR THE CONTINUING SUPPORT OF CELEBRITIES FROM ALL OVER THE WORLD. CELEBRITY SUPPORTERS INCLUDED KATY PERRY, DAME SHIRLEY BASSEY, DARREN CRISS, JUDD APATOW, ROBERT PATTINSON, MATT BOMER, DIANA ROSS, JAY ELLIS, ZOE SALDANA, GRACE JONES, MILLA JOVOVICH, MERT ALAS AND MARCUS PIGGOTT, KIM KARDASHIAN, KOURTNEY KARDASHIAN, HEIDI KLUM, ALAN CUMMING, MICHELLE RODRIGUEZ, KAROLINA KURKOVA, ALESSANDRA AMBROSIO, CAROLINE VREELAND, CANDICE SWANEPOEL, ELSA HOSK, KAREN ELSON, LAIS RIBEIRO, VICTORIA JUSTICE, WINNIE HARLOW, ALEXANDER SKARSGRD, PHARRELL WILLIAMS, MICHELLE YEOH, KYLE MACLACHLAN, NICOLE SCHERZINGER, LAY ZHANG, MARIAH CAREY, DUA LIPA, TOM JONES, CHARLI XCX, CHRIS TUCKER, CARINE ROITFELD, ANDREAS SCHAGER, HENRY GOLDING, EVA LONGORIA, ANDIE MACDOWELL, NATASHA POLY, PATRICIA ARQUETTE, ANTONIO BANDERAS, ORLANDO BLOOM, IAN BOHEN, ADRIEN BRODY, KENDALL JENNER, H.E.R., TOMMY HILFIGER, KRIS JENNER, JULIAN LENNON, ADRIANA LIMA, COCO ROCHA, SARA SAMPAIO, CHRISTOPH WALTZ, REBEL WILSON, CEELO GREEN, JOAN SMALLS, AND RITA ORA. PROGRAM SERVICE ACCOMPLISHMENTS (5) LINE 4D: PUBLIC POLICY: INFORMED BY THOROUGH RESEARCH AND ANALYSIS, AMFAR IS A HIGHLY RESPECTED ADVOCATE OF RATIONAL AND COMPASSIONATE HIV/AIDS-RELATED PUBLIC POLICY. THE FOUNDATION IS ENGAGED IN EFFORTS TO SECURE NECESSARY INCREASES IN FUNDING FOR HIV/AIDS RESEARCH AND GLOBAL HIV/AIDS PROGRAMS, EXPAND ACCESS TO TREATMENT AND CARE FOR MARGINALIZED POPULATIONS, ADVOCATE HARM REDUCTION POLICIES AIMED AT REDUCING THE SPREAD OF HIV AND HEPATITIS C (HCV) AMONG PEOPLE WHO INJECT DRUGS, AND PROTECT THE CIVIL RIGHTS OF ALL PEOPLE AFFECTED BY OR VULNERABLE TO HIV/AIDS. ENDING THE DOMESTIC HIV EPIDEMIC DURING THE 2019 STATE OF THE UNION, PRESIDENT TRUMP ANNOUNCED A PLAN TO END HIV TRANSMISSIONS IN THE U.S. BY 2030. THE ENDING THE HIV EPIDEMIC INITIATIVE (EHE) AIMS TO REDUCE HIV INFECTIONS BY 75% IN FIVE YEARS, AND BY 90% IN TEN YEARS. IN 2019, AMFAR LAUNCHED A FREE INTERACTIVE DATABASE (EHE.AMFAR.ORG) TO HELP POLICYMAKERS, PUBLIC HEALTH OFFICIALS, ADVOCATES, AND OTHER STAKEHOLDERS UNDERSTAND THE OPPORTUNITIES AND CHALLENGES ACROSS EHE JURISDICTIONS. THE EHE DATABASE INCLUDES DEMOGRAPHIC, POLICY, AND SERVICE PROVIDER INFORMATION, AND EPIDEMIOLOGICAL INDICATORS. IN 2018 THE TRUMP ADMINISTRATION PROPOSED A RULE CHANGE TO THE TITLE X NATIONAL FAMILY PLANNING PROGRAM, STATING THAT HEALTH PROVIDERS IN THE TITLE X PROGRAM "MAY NOT PERFORM, PROMOTE, REFER FOR, OR SUPPORT ABORTION." THE STIPULATION IS COMMONLY KNOWN AS THE DOMESTIC GAG RULE. IN FEBRUARY 2019, AMFAR PUBLISHED TITLE X, THE DOMESTIC GAG RULE, AND THE HIV RESPONSE, AN ISSUE BRIEF ILLUSTRATING THE BENEFITS OF THE TITLE X PROGRAM AND POTENTIAL IMPACTS OF THE GAG RULE. ANALYSIS FROM THE REPORT SHOWS THAT, IF IMPLEMENTED, THE DOMESTIC GAG RULE COULD NOT ONLY UNDERMINE WOMENS ACCESS TO REPRODUCTIVE HEALTH SERVICES, BUT ALSO IMPEDE ACCESS TO HIV TESTING FOR LOW-INCOME POPULATIONS, THREATENING THE NATIONAL RESPONSE TO THE HIV EPIDEMIC. AND IN MARCH 2019, AMFAR PUBLISHED AN ISSUE BRIEF TITLED EXPANDING ACCESS TO PRE-EXPOSURE PROPHYLAXIS (PREP) FOR ADOLESCENTS AND YOUNG ADULTS: MODELS FOR ADDRESSING CONSENT, CONFIDENTIALITY, AND PAYMENT BARRIERS. ENSURING THAT ADOLESCENTS AND YOUNG ADULTS AT RISK FOR HIV CAN ACCESS PREP IS A KEY STEP TOWARD REDUCING THE NUMBER OF HIV DIAGNOSES. HIV AND THE OPIOID EPIDEMIC AMFAR MAINTAINS AN IMPORTANT AND WIDELY USED RESOURCE ON HIV AND THE OPIOID EPIDEMIC. ITS OPIOID & HEATH INDICATORS DATABASE (OPIOID.AMFAR.ORG) IS A FREE WEB PLATFORM DESIGNED TO SUPPORT LAWMAKERS, COMMUNITIES AND ADVOCATES IN MAKING INFORMED DECISIONS ABOUT THE OPIOID EPIDEMIC AND ITS IMPACT ON HIV AND HEPATITIS C. THE SITE IS A WINDOW INTO THE OPIOID EPIDEMIC UNFOLDING IN EVERY AMERICANS BACKYARD. IT PROVIDES LOCAL TO NATIONAL STATISTICS USING RELIABLE DATA SOURCES ON NEW HIV AND HEPATITIS C INFECTIONS, OPIOID USE AND OVERDOSE DEATH RATES, AND THE AVAILABILITY OF SERVICES LIKE DRUG TREATMENT PROGRAMS AND SYRINGE EXCHANGE SERVICES. IN OCTOBER 2018, AMFAR PUBLISHED AN ANALYSIS IN HEALTH AFFAIRS ON THE LOW PERCENTAGE OF SUBSTANCE USE FACILITIES THAT TEST FOR HIV OR HEPATITIS C. THE NEW YORK TIMES PUBLISHED SEVERAL ARTICLES HIGHLIGHTING THE BIPARTISAN OPIOID BILL PASSED BY CONGRESS THAT LINKED TO AMFARS ORIGINAL HEALTH AFFAIRS ANALYSIS ON THE DEARTH OF SUBSTANCE USE TREATMENT FACILITIES THAT OFFER MEDICATION-ASSISTED TREATMENT (MAT) NATIONWIDE. THE NUMBER OF DRUG-RELATED POISONING DEATHS IN THE UNITED STATES MORE THAN TRIPLED BETWEEN 1999 AND 2017, ACCOMPANIED BY A RISE IN INJECTION DRUG USE. SINCE UPTAKE OF TREATMENT FOR SUBSTANCE USE DISORDER AND HARM REDUCTION SERVICES AT SYRINGE SERVICES PROGRAMS (SSPS) CAN REDUCE THE RISK OF HIV AND HEPATITIS C ACQUISITION, ACCESS TO SERVICES IS CRITICALLY IMPORTANT. IN NOVEMBER 2018, AMFAR PUBLISHED GETTING TO SERVICES: FAR, FAR AWAY, AN INFOGRAPHIC SHOWING HOW FAR AMERICANS MUST TRAVEL TO SUBSTANCE USE CLINICS OFFERING MAT AND SSPS. NEARLY 30% OF AMERICANS LIVE MORE THAN TEN MILES FROM A FACILITY PROVIDING MEDICATION-ASSISTED TREATMENT, AND NEARLY 80% LIVE MORE THAN TEN MILES FROM AN SSP. ACCORDING TO ONE STUDY, PEOPLE TYPICALLY DO NOT ACCESS SSPS IF THEY ARE MORE THAN TEN MILES FROM WHERE THEY LIVE. IN AUGUST 2019, AMFAR SENIOR POLICY AND MEDICAL ADVISOR DR. SUSAN BLUMENTHAL PENNED AN OP-ED ON THRIVEGLOBAL ON THE NEED FOR A STRATEGIC PLAN FOR ADDRESSING THE OPIOID EPIDEMIC PARALLELING WHAT WAS DONE FOR HIV. GLOBAL HEALTH IN OCTOBER 2018, AMFAR PUBLISHED A FIRST-OF-ITS-KIND ANALYSIS THAT ATTEMPTED TO QUANTIFY INDIRECT COSTS CHARGED BY ORGANIZATIONS IMPLEMENTING THE U.S. PRESIDENTS EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR). EXAMINING DATA FROM 2007 TO 2016, THE STUDY FOUND THAT BETWEEN $1.85 BILLION AND $4.34 BILLION WAS SPENT ON INDIRECT COSTS. THE STUDY WAS PUBLISHED IN THE PEER-REVIEWED ONLINE JOURNAL PLOS ONE, AND CALLED FOR INCREASED TRANSPARENCY IN REPORTING INDIRECT COSTS INCURRED BY PEPFAR. AT THE BIENNIAL HIV RESEARCH FOR PREVENTION CONFERENCE IN MADRID IN OCTOBER 2018, AMFAR POLICY ASSOCIATE JENNIFER SHERWOOD AND COLLEAGUES PRESENTED FINDINGS FROM A SURVEY USED TO TRACK THE IMPACT OF THE EXPANDED MEXICO CITY POLICY ON THE OPERATIONS AND SERVICE DELIVERY OF ORGANIZATIONS RECEIVING ASSISTANCE THROUGH PEPFAR. THE MEXICO CITY POLICY, OR "GLOBAL GAG RULE," WAS REINSTATED AND EXPANDED BY PRESIDENT TRUMP IN 2017. IT NOW RESTRICTS NON-U.S.-BASED OR FOREIGN NGOS FROM RECEIVING AMERICAN FINANCIAL AID IF THEY PERFORM, COUNSEL ON, OR REFER FOR ABORTION, OR ADVOCATE FOR ITS LIBERALIZATION OUTSIDE OF LIMITED EXCEPTIONS. IN JANUARY 2019, AMFAR PUBLISHED AN ISSUE BRIEF REPORTING ON DISRUPTIONS IN SERVICE PROVISION DUE TO THE EXPANDED MEXICO CITY POLICY. BASED ON THE SURVEY DESCRIBED ABOVE, AMFAR REVEALED THAT PEPFAR PARTNERS IN 31 COUNTRIES REPORTED DISRUPTIONS IN SERVICE PROVISION DUE TO THE POLICY. THESE FINDINGS HAVE SERIOUS IMPLICATIONS FOR REPRODUCTIVE HEALTH AND THE GLOBAL HIV EPIDEMIC. IN FEBRUARY 2019, AMFAR PUBLISHED A COMPANION INFOGRAPHIC, PEPFAR PROGRAMMING DISRUPTED BY EXPANDED MEXICO CITY POLICY. IN DECEMBER 2018, AMFAR LAUNCHED THE PEPFAR MONITORING, EVALUATION, AND REPORTING (MER) DATABASE (MER.AMFAR.ORG). THE MER DATABASE ENABLES POLICYMAKERS, PUBLIC HEALTH OFFICIALS, ADVOCATES, AND OTHER STAKEHOLDERS TO ACCESS A WIDE RANGE OF PROGRAMMATIC PEPFAR DATA AND INCLUDES DOWNLOADABLE PDFS, MAPS, DATA VISUALIZATIONS, AND DISTRICT-LEVEL DATA. THE NEW DATABASE COMPLEMENTS AMFARS EXISTING PEPFAR DATABASE (COPSDATA.AMFAR.ORG), WHICH HIGHLIGHTS PLANNED FUNDING BY PROGRAM AREA, COUNTRY AND ORGANIZATION FOR EACH YEAR THAT HAS BEEN PUBLICLY RELEASED. THE DATABASE IS DESIGNED TO HELP PEPFAR IN ITS EFFORTS TO INCREASE DATA TRANSPARENCY AND GENERAL PARTICIPATION IN THE PLANNING PROCESS. IN FEBRUARY 2019, AMFAR, IN CONJUNCTION WITH AVAC, PUBLISHED AN ISSUE BRIEF TITLED NEW HIV TESTING STRATEGIES IN PEPFAR COP19: ROLLOUT AND HUMAN RIGHTS CONCERNS. THE REPORT ANALYZES COUNTRY OPERATIONAL PLAN (COP) GUIDANCE FOR HIV TESTING AND RECOMMENDED POLICIES AIMED AT HELPING TO FIND HIV-POSITIVE PEOPLE WHO HAVE NOT BEEN IDENTIFIED BY OTHER TESTING PROGRAMS AND LINKING THEM TO TREATMENT. IN MAY 2019, AMFAR PUBLISHED A PAIR OF INFOGRAPHICS DEMONSTRATING THE EFFECTIVENESS OF THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA: A GLOBAL RESPONSE TO HIV REQUIRES THE GLOBAL FUND AND HOW THE GLOBAL FUND IMPROVES PEPFAR INVESTMENTS. THE TWO ORGANIZATIONS ARE THE WORLDS LARGEST AND MOST EFFECTIVE INVESTORS IN HIV TREATMENT AND PREVENTION. IAS 2019 AMFARS PUBLIC POLICY OFFICE PARTICIPATED IN THE 10TH INTERNATIONAL AIDS SOCIETY CONFERENCE ON HIV SCIENCE (IAS 2019) IN MEXICO CITY IN JULY. AMFAR VICE PRESIDENT AND DIRECTOR OF PUBLIC POLICY GREG MILLETT JOINED DR. ANTHONY FAUCI, DIRECTOR OF THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES AT A PRESS CONFERENCE ON "TRANSLATING PROGRESS INTO SUCCESS TO END THE AIDS EPIDEMIC." THE PRESS CONFERENCE COINCIDED WITH THE RELEASE OF A REPORT WITH THE SAME NAME, COAUTHORED BY AMFAR, AVAC, AND FRIENDS OF THE GLOBAL FIGHT AGAINST AIDS, TUBERCULOSIS AND MALARIA. THE REPORT SHOWS PLACES ACROSS THE GLOBAL NORTH AND SOUTH ON TRACK TO END THEIR RESPECTIVE EPIDEMICS AND THE COMMONALITIES BETWEEN THEM. MR. MILLETT ALSO SPOKE AT A JOURNALIST ROUNDTABLE SPONSORED BY AVAC, AND SHARED THE STAGE AT A SEPARATE MEETING WITH WORLD HEALTH ORGANIZATION REPRESENTATIVES AND AMBASSADOR DEBORAH BIRX, U.S. GLOBAL AIDS COORDINATOR, TO DEBATE THE ETHICS OF HIV RECENCY TESTING IN PEPFAR PROGRAMS. THE GMT INITIATIVE IMPLEMENTATION SCIENCE AWARDS IN FY2019, AMFARS GRANT MAKING THROUGH THE GMT INITIATIVE CONTINUED TO SUPPORT TWO LARGE IMPLEMENTATION SCIENCE PROJECTS AIMED AT IDENTIFYING BARRIERS TO HIV TESTING, TREATMENT, AND CARE AND STUDYING THE IMPACT OF INNOVATIVE HIV SERVICE DELIVERY MODELS FOR GAY MEN, OTHER MEN WHO HAVE SEX WITH MEN, AND TRANSGENDER INDIVIDUALS (COLLECTIVELY, GMT) IN LOW- AND MIDDLE-INCOME COUNTRIES. AMFAR HAS AWARDED $2.6 MILLION OVER THREE YEARS TO SUPPORT THE STUDIES. DR. CHRIS BEYRER OF JOHNS HOPKINS UNIVERSITY IN BALTIMORE IS LEADING A TEAM OF RESEARCHERS AND COMMUNITY-BASED SERVICES (IN COLLABORATION WITH THE INTERNATIONAL HIV/AIDS ALLIANCE MYANMAR) IN EVALUATING THE EFFECTIVENESS OF PROMISING INTERVENTIONS FOR GMT IN MYANMAR, WHERE INCREASED HIV TESTING AND TREATMENT OPPORTUNITIES ARE BECOMING AVAILABLE. THE RESEARCHERS ARE ASSESSING THE EFFECTIVENESS OF HIV SELF-TESTING DONE IN THE PRIVACY OF ONES HOME, POINT-OF-CARE CD4 TESTING, AND THE USE OF "PEER NAVIGATORS" FAMILIAR WITH THE LOCAL HEALTH SYSTEM TO HELP THOSE NEWLY DIAGNOSED GAIN ACCESS TO HIV TREATMENT AND CARE. IN BANGKOK, DR. NITTAYA PHANUPHAK AND HER TEAM AT THE THAI RED CROSS AIDS RESEARCH CENTRE ARE WORKING TO SHOW HOW INNOVATIVE TECHNOLOGIES SUCH AS GMT-TARGETED WEBSITES USING ONLINE COUNSELING AND SUPPORT CAN BE UTILIZED TO INCREASE RATES OF HIV TESTING AND REFERRALS TO PREVENTION AND TREATMENT PROGRAMS. WORKING IN COLLABORATION WITH ADAMS LOVE, A WEB-BASED HEALTH PLATFORM FOR GMT INDIVIDUALS, AND TWO COMMUNITY-BASED ORGANIZATIONS (SERVICE WORKERS IN GROUP/SWING AND THE RAINBOW SKY ASSOCIATION OF THAILAND), THE TEAM IS COMPARING THE EFFECTIVENESS OF ONLINE SERVICES AND SUPPORT INTERVENTIONS WITH TRADITIONAL CLINIC-BASED HIV SERVICES, AND A HYBRID MODEL THAT COMBINES ELEMENTS OF BOTH STRATEGIES. POLICIES FORM 990, PART VI, SECTION B LINE 11 - THE FORM 990 WAS PREPARED BY A NATIONALLY RENOWNED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. A COPY OF THE DRAFT FORM 990 WAS CIRCULATED TO THE FULL BOARD OF TRUSTEES FOR DISCUSSION AND COMMENT. EACH BOARD MEMBER WAS PROVIDED AMPLE OPPORTUNITY TO COMMENT ON THE INFORMATION CONTAINED IN THE 990 PRIOR TO ITS FILING WITH THE INTERNAL REVENUE SERVICE. LINE 12 - EACH OFFICER, DIRECTOR, TRUSTEE AND KEY EMPLOYEE OF AMFAR ("FOUNDATION") IS REQUIRED TO ANNUALLY DISCLOSE ANY CONFLICTS OF INTEREST THAT ARISE BY VIRTUE OF EMPLOYMENT, BOARD SERVICE, OR POSITION WITH THE FOUNDATION. THE FOUNDATION MONITORS COMPLIANCE WITH ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL QUESTIONNAIRE/DISCLOSURE STATEMENT THAT IS DISTRIBUTED TO THESE INDIVIDUALS. POTENTIAL CONFLICTS ARE INVESTIGATED IMMEDIATELY. LINE 15 - AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. AMFAR'S last independent compensation study was conducted in November of 2019 to ensure that the President & CEO's compensation is reasonable given the market in which the Foundation operates. DISCLOSURE FORM 990, PART VI, SECTION C LINE 19 - AMFAR MAKES ITS FORM 990 AVAILABLE TO THE PUBLIC BY RETAINING A COPY AT ITS PLACE OF BUSINESS AND ON ITS WEBSITE, WWW.AMFAR.ORG. THE FORM 990 IS LIKEWISE PUBLISHED ON THE INTERNET AT WWW.GUIDESTAR.ORG. THE FOUNDATION'S FINANCIAL STATEMENTS ARE MADE AVAILABLE IN ITS ANNUAL REPORT AND ON ITS WEBSITE. THE FOUNDATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE NOT ORDINARILY MADE AVAILABLE TO THE PUBLIC, BUT, IF REQUESTED, WILL BE PROVIDED AT MANAGEMENT'S DISCRETION. FUNCTIONAL EXPENSES PART IX, LINES 1 & 3 THE FOUNDATION FOR AIDS RESEARCH REPORTS ITS GRANTS NET OF GRANT RETURNS OR RECOVERIES. PERIODICALLY, GRANTS REMITTED TO CHARITABLE ORGANIZATIONS ARE RETURNED TO AMFAR FOR A VARIETY OF REASONS. ON SCHEDULES F & I, GRANTS ARE REPORTED IRRESPECTIVE OF WHETHER THEY WERE ULTIMATELY RETURNED TO AMFAR SINCE CATEGORIZING THE "RETURNED" AMOUNTS WOULD BE TIME CONSUMING. THEREFORE, AMOUNTS REPORTED ON PART IX, LINE 1 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE I; AMOUNTS REPORTED ON PART IX, LINE 3 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE F.